U.S. patent application number 13/533734 was filed with the patent office on 2012-11-08 for porphyrin catalysts and methods of use thereof.
Invention is credited to John T. Groves.
Application Number | 20120283236 13/533734 |
Document ID | / |
Family ID | 39580333 |
Filed Date | 2012-11-08 |
United States Patent
Application |
20120283236 |
Kind Code |
A1 |
Groves; John T. |
November 8, 2012 |
Porphyrin Catalysts and Methods of Use Thereof
Abstract
This invention provides a novel class of substituted macrocyclic
porphyrin compounds. The compounds are useful as peroxynitrite
decomposition catalysts. Pharmaceutical compositions, and methods
of making and using the compounds, or a pharmaceutically acceptable
salt, hydrate, or prodrug thereof are also described.
Inventors: |
Groves; John T.; (Princeton,
NJ) |
Family ID: |
39580333 |
Appl. No.: |
13/533734 |
Filed: |
June 26, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12311640 |
Dec 23, 2009 |
8232267 |
|
|
PCT/US2007/021445 |
Oct 5, 2007 |
|
|
|
13533734 |
|
|
|
|
60850179 |
Oct 6, 2006 |
|
|
|
Current U.S.
Class: |
514/185 ;
435/375; 514/333 |
Current CPC
Class: |
A61P 9/10 20180101; A61P
7/00 20180101; A61P 29/00 20180101; A61P 9/04 20180101; A61P 25/16
20180101; A61P 35/00 20180101; A61P 3/06 20180101; C07F 3/003
20130101; A61P 9/00 20180101; A61P 25/28 20180101; C07D 487/22
20130101; A61P 37/06 20180101; A61P 37/00 20180101; A61P 3/10
20180101; A61P 19/02 20180101; C07F 15/025 20130101; A61P 3/08
20180101; A61P 25/00 20180101 |
Class at
Publication: |
514/185 ;
435/375; 514/333 |
International
Class: |
A61K 31/555 20060101
A61K031/555; A61K 31/444 20060101 A61K031/444; A61P 25/28 20060101
A61P025/28; A61P 25/00 20060101 A61P025/00; A61P 9/10 20060101
A61P009/10; A61P 25/16 20060101 A61P025/16; A61P 29/00 20060101
A61P029/00; A61P 19/02 20060101 A61P019/02; A61P 7/00 20060101
A61P007/00; A61P 9/00 20060101 A61P009/00; A61P 37/06 20060101
A61P037/06; A61P 9/04 20060101 A61P009/04; A61P 3/10 20060101
A61P003/10; A61P 35/00 20060101 A61P035/00; C12N 5/02 20060101
C12N005/02 |
Goverment Interests
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with Government support under NIH
Grant GM 36298 awarded by the National Institutes of Health. The
government has certain rights in the invention.
Claims
1. A method of lowering peroxynitrite levels in a cell or tissue,
the method comprising contacting said cell or tissue with a
compound of Formula I in an amount sufficient to lower
peroxynitrite levels in said cell or tissue: ##STR00019## or a
pharmaceutically acceptable base or acid addition salt, hydrate,
ester, solvate, or stereoisomer, or mixtures thereof, wherein at
least one of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is
independently selected from the group consisting of
CH.sub.2C(O)NR.sub.5R.sub.6 and (CH.sub.2CH.sub.2O).sub.tCH.sub.3,
wherein t is 1, 2, 4, 5, 6, 7, 8, 9, or 10, and the remaining
R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are hydrogen; R.sub.5 and
R.sub.6 are selected from the group consisting of H,
CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2COO.sup.-, (CH.sub.2).sub.n--X, (CH.sub.2).sub.n--Y,
(CH.sub.2).sub.nR.sub.9--X, (CH.sub.2).sub.nR.sub.9--Y,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, (OCH.sub.2CH.sub.2).sub.m--X,
(OCH.sub.2CH.sub.2).sub.m--Y, Y.sub.2--X, Y.sub.2C(Z.sub.1).sub.3,
further wherein: Z.sub.1 is CH.sub.2OCH.sub.2(CH.sub.2).sub.nX or
CH.sub.2OCH.sub.2(CH.sub.2).sub.nY;
(CH.sub.2).sub.nC(O)Y.sub.2C(Z.sub.2).sub.3, wherein: Z.sub.2 is
CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.4).sub.3 and Z.sub.4 is
CH.sub.2OCH.sub.2CH.sub.2X;
(CH.sub.2).sub.nC(O)--Y.sub.2--C(Z.sub.5).sub.3, wherein: Z.sub.5
is CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.6).sub.3 and Z.sub.6
is
CH.sub.2OCH.sub.2CH.sub.2C(O)O(CH.sub.2CH.sub.2O).sub.mCH.sub.2CH.sub.2O;
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.3,
(CH.sub.2).sub.nOCH.sub.2CH(CH.sub.2OH).sub.2,
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.2(CH.sub.3),
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2OH).sub.3].sub.3,
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2O[CH.sub.2CH.sub.2O-
].sub.mCH.sub.2CH.sub.2OX).sub.3].sub.3, CH.sub.2CONH--Y,
CH.sub.2CO--Y, CH.sub.2CO(CH.sub.2).sub.p--Y; alkyl, cycloalkyl,
and aralkyl; wherein n is an integer selected from 1, 2, 3, 4, 5,
6, 7, 8, 9, and 10; m is an integer from 1 to 200, and p is 1 or 2;
X is COOH, COOR', CONH.sub.2, CONHR', CONR'.sub.2,
CO(CH.sub.2).sub.pR', OPO.sub.3H.sub.2, PO.sub.3H.sub.2, SO.sub.3H,
NH.sub.2, NR'.sub.2, or NR'.sub.3.sup.+, a steroid, an amino acid,
an oligosaccharide, a peptide, or a polycarboxylic acid, further
wherein R' is alkyl, CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3, (CH.sub.2).sub.n--X,
(CH.sub.2).sub.n--Y, (CH.sub.2).sub.nAr--X, (CH.sub.2).sub.nAr--Y,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, (OCH.sub.2CH.sub.2).sub.m--X,
(OCH.sub.2CH.sub.2).sub.m--Y, Y.sub.2--X, Y.sub.2C(Z.sub.1).sub.3,
further wherein: Z.sub.1 is CH.sub.2OCH.sub.2(CH.sub.2).sub.nX or
CH.sub.2OCH.sub.2(CH.sub.2).sub.nY;
(CH.sub.2).sub.nC(O)Y.sub.2C(Z.sub.2).sub.3, wherein: Z.sub.2 is
CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.4).sub.3 and Z.sub.4 is
CH.sub.2OCH.sub.2CH.sub.2X;
(CH.sub.2).sub.nC(O)--Y.sub.2--C(Z.sub.5).sub.3, wherein: Z.sub.5
is CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.6).sub.3 and Z.sub.6
is
CH.sub.2OCH.sub.2CH.sub.2C(O)O(CH.sub.2CH.sub.2O).sub.nCH.sub.2CH.sub.2O;
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.3,
(CH.sub.2).sub.nOCH.sub.2CH(CH.sub.2OH).sub.2,
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.2(CH.sub.3),
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2OH).sub.3].sub.3,
(CH.sub.2).sub.mOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2O[CH.sub.2CH.sub.2O-
].sub.mCH.sub.2CH.sub.2OX).sub.3].sub.3, CH.sub.2CONH--Y,
CH.sub.2CO--Y, and CH.sub.2CO(CH.sub.2).sub.p--Y; Y is OH or
(OCH.sub.2CH.sub.2).sub.m--W.sub.1 or
(CH.sub.2CH.sub.2).sub.m--W.sub.2; where W.sub.1 is OH, or
(OCH.sub.2CH.sub.2).sub.mOH and W.sub.2 is OR'', further wherein
R'' is an alkyl group; Y.sub.2 is selected from the group
consisting of (CH.sub.2).sub.nO, (CH.sub.2).sub.nNH, and
(CH.sub.2).sub.nS, CH.sub.2CONH, CH.sub.2COO, or
CH.sub.2CO(CH.sub.2).sub.p; R.sub.9 is substituted phenyl,
unsubstituted phenyl, substituted napthyl, or unsubstituted
naphthyl; L.sub.1 and L.sub.2 are, independently, absent, halide,
oxo, OH.sub.2, hydroxo, CN, OPO.sub.3H or alcohol; and M is absent,
Mn or Fe; provided that R.sub.5 and R.sub.6 are not both alkyl.
2. The method of claim 1, wherein R.sub.1, R.sub.2, R.sub.3, and
R.sub.4 are each CH.sub.2C(O)NR.sub.5R.sub.6.
3. The method of claim 1, wherein one of R.sub.5 or R.sub.6 is
H.
4. The method of claim 1, wherein one of R.sub.5 or R.sub.6 is
selected from aralkyl, alkyl, cycloalkyl, substituted cycloalkyl,
and CH.sub.2CH.sub.2OCH.sub.3.
5. The method of claim 4, wherein aralkyl is
(CR.sub.7R.sub.8).sub.s--R.sub.9, wherein R.sub.7 and R.sub.8 are,
independently, selected from H, alkyl, OH, and halogen, and s is 1,
2, 3, 4, 5, 6, 7, 8, 9, or 10.
6. The method of claim 5, wherein aralkyl is ##STR00020##
7. The method of claim 4, wherein one of R.sub.5 or R.sub.6 is
selected from alkyl, cycloalkyl, and substituted cycloalkyl.
8. The method of claim 7, wherein cycloalkyl or substituted
cycloalkyl is a bicyclic ring system.
9. The method of claim 8, wherein the bicyclic ring system is
bicycle[2.2.1]heptane.
10. The method of claim 8, wherein the bicyclic ring system is
1,7,7-trimethylbicyclo[2.2.1]heptane.
11. The method of claim 4, wherein one of R.sub.5 or R.sub.6 is
CH.sub.2CH.sub.2OCH.sub.3.
12. The method of claim 1, wherein R.sub.1, R.sub.2, R.sub.3, and
R.sub.4 are (CH.sub.2CH.sub.2O).sub.tCH.sub.3.
13. The method of claim 1, wherein t=1.
14. The method of claim 1, wherein the compound is an
.alpha..alpha..beta..beta. atropisomer.
15. The method of claim 1, wherein the compound is selected from
##STR00021## ##STR00022## wherein L.sub.1 and L.sub.2 are,
independently, absent, halide, oxo, OH.sub.2, hydroxo, CN,
OPO.sub.3H or alcohol; and M is absent, Mn or Fe.
16. A method of treating or inhibiting the development of a
pathology associated with peroxynitrite damage in a subject, the
method comprising administering to a subject in need thereof a
therapeutically effective amount of the compound of Formula I:
##STR00023## or a pharmaceutically acceptable base or acid addition
salt, hydrate, ester, solvate, or stereoisomer, or mixtures
thereof, wherein at least one of R.sub.1, R.sub.2, R.sub.3, and
R.sub.4 is independently selected from the group consisting of
CH.sub.2C(O)NR.sub.5R.sub.6 and (CH.sub.2CH.sub.2O).sub.tCH.sub.3,
wherein t is 1, 2, 4, 5, 6, 7, 8, 9, or 10, and the remaining
R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are hydrogen; R.sub.5 and
R.sub.6 are selected from the group consisting of H,
CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2COO.sup.-, (CH.sub.2).sub.n--X, (CH.sub.2).sub.n--Y,
(CH.sub.2).sub.nR.sub.9--X, (CH.sub.2).sub.nR.sub.9--Y,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, (OCH.sub.2CH.sub.2).sub.n, --X,
(OCH.sub.2CH.sub.2).sub.m--Y, Y.sub.2--X, Y.sub.2C(Z.sub.1).sub.3,
further wherein: Z.sub.1 is CH.sub.2OCH.sub.2(CH.sub.2).sub.nX or
CH.sub.2OCH.sub.2(CH.sub.2).sub.nY;
(CH.sub.2).sub.nC(O)Y.sub.2C(Z.sub.2).sub.3, wherein: Z.sub.2 is
CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.4).sub.3 and Z.sub.4 is
CH.sub.2OCH.sub.2CH.sub.2X;
(CH.sub.2).sub.nC(O)--Y.sub.2--C(Z.sub.5).sub.3, wherein: Z.sub.5
is CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.6).sub.3 and Z.sub.6
is
CH.sub.2OCH.sub.2CH.sub.2C(O)O(CH.sub.2CH.sub.2O).sub.mCH.sub.2CH.sub.2O.-
sup.-; (CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.3,
(CH.sub.2).sub.nOCH.sub.2CH(CH.sub.2OH).sub.2,
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.2(CH.sub.3),
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2OH).sub.3].sub.3,
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2O[CH.sub.2CH.sub.2O-
].sub.mCH.sub.2CH.sub.2OX).sub.3].sub.3, CH.sub.2CONH--Y,
CH.sub.2CO--Y, CH.sub.2CO(CH.sub.2).sub.p--Y; alkyl, cycloalkyl,
and aralkyl; wherein n is an integer selected from 1, 2, 3, 4, 5,
6, 7, 8, 9, and 10; m is an integer from 1 to 200, and p is 1 or 2;
X is COOH, COOR', CONH.sub.2, CONHR', CONR'.sub.2,
CO(CH.sub.2).sub.pR', OPO.sub.3H.sub.2, PO.sub.3H.sub.2, SO.sub.3H,
NH.sub.2, NR'.sub.2, or NR'.sub.3.sup.+, a steroid, an amino acid,
an oligosaccharide, a peptide, or a polycarboxylic acid, further
wherein R' is alkyl, CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3, (CH.sub.2).sub.n--X,
(CH.sub.2).sub.n--Y, (CH.sub.2).sub.nAr--X, (CH.sub.2).sub.nAr--Y,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, (OCH.sub.2CH.sub.2).sub.m--X,
(OCH.sub.2CH.sub.2).sub.m--Y, Y.sub.2--X, Y.sub.2C(Z.sub.1).sub.3,
further wherein: Z.sub.1 is CH.sub.2OCH.sub.2(CH.sub.2).sub.nX or
CH.sub.2OCH.sub.2(CH.sub.2).sub.nY;
(CH.sub.2).sub.nC(O)Y.sub.2C(Z.sub.2).sub.3, wherein: Z.sub.2 is
CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.4).sub.3 and Z.sub.4 is
CH.sub.2OCH.sub.2CH.sub.2X;
(CH.sub.2).sub.nC(O)--Y.sub.2--C(Z.sub.5).sub.3, wherein: Z.sub.5
is CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.6).sub.3 and Z.sub.6
is
CH.sub.2OCH.sub.2CH.sub.2C(O)O(CH.sub.2CH.sub.2O).sub.mCH.sub.2CH.sub.2O.-
sup.-; (CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.3,
(CH.sub.2).sub.nOCH.sub.2CH(CH.sub.2OH).sub.2,
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.2(CH.sub.3),
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2OH).sub.3].sub.3,
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2O[CH.sub.2CH.sub.2O-
].sub.nCH.sub.2CH.sub.2OX).sub.3].sub.3, CH.sub.2CONH--Y,
CH.sub.2CO--Y, and CH.sub.2CO(CH.sub.2).sub.p--Y; Y is OH or
(OCH.sub.2CH.sub.2).sub.m--W.sub.1 or
(CH.sub.2CH.sub.2).sub.m--W.sub.2; where W.sub.1 is OH, or
(OCH.sub.2CH.sub.2).sub.mOH and W.sub.2 is OR'', further wherein
R'' is an alkyl group; Y.sub.2 is selected from the group
consisting of (CH.sub.2).sub.nO, (CH.sub.2).sub.nNH, and
(CH.sub.2).sub.nS, CH.sub.2CONH, CH.sub.2COO, or
CH.sub.2CO(CH.sub.2).sub.p; R.sub.9 is substituted phenyl,
unsubstituted phenyl, substituted napthyl, or unsubstituted
naphthyl; L.sub.1 and L.sub.2 are, independently, absent, halide,
oxo, OH.sub.2, hydroxo, CN, OPO.sub.3H or alcohol; and M is absent,
Mn or Fe; provided that R.sub.5 and R.sub.6 are not both alkyl.
17. The method of claim 16, wherein said pathology is selected from
the group consisting of Alzheimer's disease, amyotrophic lateral
sclerosis, stroke, AIDS dementia, Huntington's disease,
atherosclerosis, inflammation, arthritis, neurodegeneration,
sepsis, autoimmune diseases, cancer, ischemia-reperfusion injury,
septic shock, diabetes, diabetic vascular complications, diabetic
cardiomyopathy, diabetic neuropathy, hyperglycemia,
pathophysiological conditions of the heart, acute myocardial
infarction, chronic ischemic heart failure, doxorubicin-induced
cardiac dysfunction, oxidative stress, obliterative bronchiolitis,
colitis, vascular dysfunction, myocardial dysfunction, myocardial
necrosis, and chronic graft rejection.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 12/311,640, filed Dec. 23, 2009, which is a
U.S. national stage application, filed under 35 U.S.C. 371, of
International Application No. PCT/US2007/021445, filed Oct. 5,
2007, which claims priority to U.S. provisional application Ser.
No. 60/850,179, filed Oct. 6, 2006, the entire disclosures of each
are incorporated by reference herein.
FIELD OF THE INVENTION
[0003] The invention relates in general to substituted porphyrin
compounds.
BACKGROUND OF THE INVENTION
[0004] The peroxynitrite ion (ONOO.sup.-) is a potent oxidant
formed by the combination of nitric oxide (NO) and the superoxide
anion (O.sub.2).sup.-. NO has been shown to be generated by
numerous cell types, such as macrophages, neutrophils, hepatocytes
and endothelial cells. The direct combination of NO with O.sub.2
produces the peroxynitrite ion (ONOO.sup.-), which decomposes
rapidly under physiological conditions to oxidizing intermediates.
These oxidizing intermediates can damage biological targets.
[0005] Pathological consequences associated with damage to
biological targets can include the oxidizing or nitrating of
proteins, lipids and DNA. ONOO.sup.- crosses lipid membranes at a
rate significantly faster than the rates of other known oxidants,
indicating that this oxidant can travel distances of cellular
dimensions. Thus, even in the presence of biological membranes,
ONOO.sup.- can have free access to cellular interiors. ONOO.sup.-
is also known to nitrate tyrosine residues in proteins, and to
oxidize sulfhydryls, methionines and macromolecules such as, for
example, metalloenzymes, DNA, and lipids.
[0006] In light of this reactivity, ONOO.sup.- has been implicated
in a variety of diseases. These diseases include, e.g.,
neurodegenerative disorders such as Alzheimer's disease,
amyotrophic lateral sclerosis, stroke, AIDS dementia and
Huntington's disease; heart diseases such as atherosclerosis;
chronic inflammation and autoimmune diseases such as arthritis,
inflammatory bowel disease, and acute respiratory disease syndrome;
cancer; ischemia-reperfusion injury; septic shock; and chronic
rejection of renal grafts.
SUMMARY OF THE INVENTION
[0007] The invention is based in part on the discovery of
substituted 2-pyridyl porphyrin compounds that are effective
peroxynitrite decomposition catalysts. 2-pyridyl porphyrin
compounds have one or more of the properties of high catalytic
activity, high stability and enhanced lifetime in the blood pool,
advantageous tissue distribution, and low toxicity. The
peroxynitrite decomposition catalysts can be used to treat a
variety of conditions and diseases, including those known to result
from the accumulation of peroxynitrite.
[0008] Accordingly, in one aspect the invention provides a compound
having the Formula I:
##STR00001##
or a pharmaceutically acceptable base or acid addition salt,
hydrate, ester, solvate, prodrug, metabolite, or stereoisomer, or
mixtures thereof. In one embodiment, at least one of R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 is independently selected from the
group consisting of CH.sub.2C(O)NR.sub.5R.sub.6 and
(CH.sub.2CH.sub.2O).sub.tCH.sub.3 and the remaining R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 are hydrogen. t is selected from 1,
2, 4, 5, 6, 7, 8, 9, and 10.
[0009] R.sub.5 and R.sub.6 are selected from the group consisting
of H, CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2OCH.sub.2CH.sub.2
OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2COO.sup.-, (CH.sub.2).sub.n--X, (CH.sub.2).sub.m--Y,
(CH.sub.2).sub.nR.sub.9--X, (CH.sub.2).sub.nR.sub.9--Y,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, (OCH.sub.2CH.sub.2).sub.m--X,
(OCH.sub.2CH.sub.2).sub.m--Y, Y.sub.2--X, Y.sub.2C(Z.sub.1).sub.3,
further wherein: Z.sub.1 is CH.sub.2OCH.sub.2(CH.sub.2).sub.nX or
CH.sub.2OCH.sub.2(CH.sub.2).sub.nY;
(CH.sub.2).sub.nC(O)Y.sub.2C(Z.sub.2).sub.3, wherein: Z.sub.2 is
CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.4).sub.3 and Z.sub.4 is
CH.sub.2OCH.sub.2CH.sub.2X;
(CH.sub.2).sub.nC(O)--Y.sub.2--C(Z.sub.5).sub.3, wherein: Z.sub.5
is CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.6).sub.3 and Z.sub.6
is
CH.sub.2OCH.sub.2CH.sub.2C(O)O(CH.sub.2CH.sub.2O).sub.mCH.sub.2CH.sub.2O.-
sup.-; (CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.3,
(CH.sub.2).sub.nOCH.sub.2CH(CH.sub.2OH).sub.2,
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.2(CH.sub.3),
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2OH).sub.3].sub.3,
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2O[CH.sub.2CH.sub.2O-
].sub.mCH.sub.2CH.sub.2OX).sub.3].sub.3, CH.sub.2CONH--Y,
CH.sub.2CO--Y, CH.sub.2CO(CH.sub.2).sub.p--Y; alkyl, cycloalkyl,
and aralkyl.
[0010] n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and
10. m is an integer from 1 to 200. p is 1 or 2. X is COOH, COOR',
CONH.sub.2, CONHR', CONR'.sub.2, CO(CH.sub.2).sub.pR',
OPO.sub.3H.sub.2, PO.sub.3H.sub.2, SO.sub.3H, NH.sub.2, NR'.sub.2,
or NR'.sub.3.sup.+, a steroid, an amino acid, an oligosaccharide, a
peptide, or a polycarboxylic acid. R' is alkyl
CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3, (CH.sub.2).sub.n--X,
(CH.sub.2).sub.n--Y, (CH.sub.2).sub.nAr--X, (CH.sub.2).sub.nAr--Y,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, (OCH.sub.2CH.sub.2).sub.n--X,
(OCH.sub.2CH.sub.2).sub.m--Y, Y.sub.2--X, Y.sub.2C(Z.sub.1).sub.3,
further wherein: Z.sub.1 is CH.sub.2OCH.sub.2(CH.sub.2).sub.nX or
CH.sub.2OCH.sub.2(CH.sub.2).sub.nY;
(CH.sub.2).sub.nC(O)Y.sub.2C(Z.sub.2).sub.3, wherein: Z.sub.2 is
CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.4).sub.3 and Z.sub.4 is
CH.sub.2OCH.sub.2CH.sub.2X;
(CH.sub.2).sub.nC(O)--Y.sub.2--C(Z.sub.5).sub.3, wherein: Z.sub.5
is CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.6).sub.3 and Z.sub.6
is
CH.sub.2OCH.sub.2CH.sub.2C(O)O(CH.sub.2CH.sub.2O).sub.mCH.sub.2CH.sub.2O.-
sup.-; (CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.3,
(CH.sub.2).sub.nOCH.sub.2CH(CH.sub.2OH).sub.2,
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.2(CH.sub.3),
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2OH).sub.3].sub.3,
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2O[CH.sub.2CH.sub.2O-
].sub.mCH.sub.2CH.sub.2OX).sub.3].sub.3, CH.sub.2CONH--Y,
CH.sub.2CO--Y, and CH.sub.2CO(CH.sub.2).sub.p--Y;.
[0011] Y is OH or (OCH.sub.2CH.sub.2).sub.m--W.sub.1 or
(CH.sub.2CH.sub.2).sub.m--W.sub.2; where W.sub.1 is OH, or
(OCH.sub.2CH.sub.2).sub.mOH and W.sub.2 is OR''. R'' is an alkyl
group. Y.sub.2 is selected from the group consisting of
(CH.sub.2).sub.nO, (CH.sub.2).sub.nNH, and (CH.sub.2).sub.nS,
CH.sub.2CONH, CH.sub.2COO, or CH.sub.2CO(CH.sub.2).sub.p.
[0012] R.sub.9 is substituted phenyl, unsubstituted phenyl,
substituted napthyl, or unsubstituted naphthyl. L.sub.1 and L.sub.2
are, independently, absent, halide, oxo, OH.sub.2, hydroxo, CN,
OPO.sub.3H or alcohol; and M is absent, Mn or Fe. In one
embodiment, R.sub.5 and R.sub.6 are not both alkyl.
[0013] In one embodiment, at least one of R.sub.1, R.sub.2,
R.sub.3, or R.sub.4 is CH.sub.2C(O)NR.sub.5R.sub.6. In another
embodiment, at least two of R.sub.1, R.sub.2, R.sub.3, or
R.sub.4CH.sub.2C(O)NR.sub.5R.sub.6. In another embodiment, at least
three of R.sub.1, R.sub.2, R.sub.3, or R.sub.4 are
CH.sub.2C(O)NR.sub.5R.sub.6. In another embodiment, R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 are each
CH.sub.2C(O)NR.sub.5R.sub.6.
[0014] In one embodiment, M is Mn or Fe. In another embodiment, M
is absent.
[0015] In one embodiment, one of R.sub.5 or R.sub.6 is H. In
another embodiment, one of R.sub.5 or R.sub.6 is selected from
aralkyl, alkyl, cycloalkyl, substituted cycloalkyl, and
CH.sub.2CH.sub.2OCH.sub.3. In one embodiment, one of R.sub.5 or
R.sub.6 is aralkyl.
[0016] In another embodiment, aralkyl is
(CR.sub.7R.sub.8).sub.s--R.sub.9. In one embodiment, R.sub.7 and
R.sub.8 are, independently, selected from H, alkyl, OH, and
halogen. In another embodiment, s is 1, 2, 3, 4, 5, 6, 7, 8, 9, or
10. In one embodiment, one of R.sub.7 or R.sub.8 is H. In another
embodiment, one of R.sub.7 or R.sub.8 is alkyl. In one embodiment,
R.sub.9 is phenyl. In another embodiment, s is 1. In one
embodiment, aralkyl is
##STR00002##
In another embodiment, aralkyl is
##STR00003##
In another embodiment, aralkyl is
##STR00004##
[0017] In one embodiment, one of R.sub.5 or R.sub.6 is selected
from alkyl, cycloalkyl, or substituted cycloalkyl. In another
embodiment, cycloalkyl or substituted cycloalkyl is a bicyclic or
tricyclic ring system. In one embodiment, the bicyclic ring system
is bicycle[2.2.1]heptane. In another embodiment, the bicyclic ring
system is 1,7,7-trimethylbicyclo[2.2.1]heptane. In one embodiment,
one of R.sub.5 or R.sub.6 is CH.sub.2CH.sub.2OCH.sub.3.
[0018] In one embodiment, at least one of R.sub.1, R.sub.2,
R.sub.3, or R.sub.4 is (CH.sub.2CH.sub.2O).sub.tCH.sub.3. In
another embodiment, at least two of R.sub.1, R.sub.2, R.sub.3, or
R.sub.4 are (CH.sub.2CH.sub.2O).sub.tCH.sub.3. In another
embodiment, at least three of R.sub.1, R.sub.2, R.sub.3, or R.sub.4
are (CH.sub.2CH.sub.2O).sub.tCH.sub.3. In another embodiment,
R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are
(CH.sub.2CH.sub.2O).sub.tCH.sub.3. In one embodiment, t is 1.
[0019] In one embodiment, the compound is a mixture of
atropoisomers .alpha..alpha..alpha..alpha.,
.alpha..alpha..alpha..beta., .alpha..alpha..beta..beta., and
.alpha..beta..alpha..beta.. In another embodiment, the compound is
an .alpha..alpha..beta..beta. atropisomer. In one embodiment, the
compound is selected from
##STR00005## ##STR00006##
[0020] wherein L.sub.1 and L.sub.2 are, independently, absent,
halide, oxo, OH.sub.2, hydroxo, CN, OPO.sub.3H or alcohol; and M is
absent, Mn or Fe.
[0021] One aspect of the invention includes a pharmaceutical
composition comprising the compound of formula I and a
pharmaceutically acceptable carrier. Another embodiment of the
invention includes a method of lowering peroxynitrite levels in a
cell or tissue, the method comprising contacting said cell or
tissue with a compound of formula I in an amount sufficient to
lower peroxynitrite levels in said cell or tissue. Another
embodiment includes a method of treating or inhibiting the
development of a pathology associated with peroxynitrite damage in
a subject, the method comprising administering to a subject in need
thereof a therapeutically effective amount of the compound of
formula I. In another embodiment, the pathology is selected from
the group consisting of Alzheimer's disease, amyotrophic lateral
sclerosis, stroke, AIDS dementia, Huntington's disease,
atherosclerosis, inflammation, arthritis, neurodegeneration,
sepsis, autoimmune diseases, cancer, ischemia-reperfusion injury,
septic shock, diabetes, diabetic vascular complications, diabetic
cardiomyopathy, diabetic neuropathy, hyperglycemia,
pathophysiological conditions of the heart, acute myocardial
infarction, chronic ischemic heart failure, doxorubicin-induced
cardiac disfunction, oxidative stress, obliterative bronchiolitis,
colitis, vascular dysfunction, myocardial dysfunction, myocardial
necrosis, and chronic graft. In another embodiment, the subject is
a human.
[0022] The details of one or more embodiments of the invention are
set forth in the accompanying description below. Although any
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the invention, the
preferred methods and materials are now described. Other features,
objects, and advantages of the invention will be apparent from the
description and from the claims. In the specification and the
appended claims, the singular forms also include the plural unless
the context clearly dictates otherwise. Unless defined otherwise,
all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art
to which this invention belongs. All patents and publications cited
in this specification are incorporated by reference.
DETAILED DESCRIPTION OF THE INVENTION
[0023] The invention provides novel substituted macrocyclic
compounds that can be complexed to a metal to form metallic
compounds. The compounds are useful as e.g., peroxynitrite
decomposition catalysts. The compounds include porphyrin complexes
containing substituted 2-pyridine substituents.
[0024] The invention is based in part on the discovery that
substituted 2-pyridyl porphyrins are unexpectedly effective
peroxynitrite decomposition catalysts. Substituents on compounds as
described herein can result in increased biocompatibility, which
can be characterized as producing at least one of the following
effects: (1) enhancement of the ONOO.sup.- decomposition activity
of the complex; (2) enhanced stability and half-life in vivo; (3)
optimized tissue distribution throughout the body; and (4) lowered
toxicity when administered to a subject. In some embodiments, the
substituted compounds are present in liposomes.
[0025] Porphyrin compounds have a wide range of applications as
water-soluble oxidation catalysts (Meunier, B. Chem. Rev. 2004,
104, 3947-3980; Jin, N. J. Am. Chem. Soc. 1999, 121, 2923-2924;
Wietzerbin, K. Inorg. Chem. 1999, 38, 4123-4127; Prado-Manso, C. J.
Mol. Catal. A: Chem. 1999, 150, 251-266) and as hosts for the
molecular recognition of small molecules in water (Imai, H. Inorg.
Chem. 2004, 43, 1211-1213, Mizutani, T. Bull. Chem. Soc. Jpn. 1998,
71, 413-418, Mikros, F. Inorg. Chim. Acta 1988, 153, 199-200).
Further, some porphyrins have shown considerable promise as
therapeutic agents such as superoxide dismutase mimics
(Batainic-Haberle, I. J. Chem. Soc., Dalton Trans. 2004, 1696-1702;
Spasojevic, I. J. Biol. Chem. 2003, 278, 6831-6837; Kachadourian,
R. J. Chromatogr. B 2002, 767, 61-67), photosensitizers (Caminos,
D. A. J. Porphyrins Phthalocyanines 2005, 9, 334-342; Benov, L.
Arch. Biochem. Biophys. 2002, 402, 159-165; Pandey, R. In The
Porphyrin Handbook; Kadish, K., Smith, K., Guilard, R., Eds.;
Academic Press: 2000; Vol. 6, p 157-230; Valduga, G. Biochem. and
Biophys. Res. Commun. 1999, 256, 84-88; Jori, G. Cancer Lett. 1984,
24, 291-297), DNA cleavers (Maraval, A. Org. Biomol. Chem. 2003, 1,
921-927; Hartmann, M. J. Biol. Inorg. Chem. 1997, 427-432, Fiel, R.
J. Biochem. Biophys. Res. Commun. 1982, 107, 1067-1074) and
peroxynitrite decomposition catalysts (Szabo, C. Mol. Med. 2002, 8,
571-580; Shimanovich, R. J. Am. Chem. Soc. 2001, 123, 3613-3614;
Fridovich, I. Chem. Res. Toxicol. 1999, 12, 442-449; Crow, J. P.
Arch. Biochem. Biophys. 1999, 371, 41-52; Groves, J. J. Am. Chem.
Soc. 1998, 120, 7493-7501). Alkylation of the pyridyl nitrogen of
meso-(pyridyl)-porphyrins (Hambrigh, P. Inorg. Chem. 1970, 9,
1757-1761) is one attractive synthetic strategy to generate
cationic porphyrins. Metallated
meso-tetrakis-(N-alkylpyridinium-2-yl)-porphyrins are of particular
interest since they have been shown to have superior superoxide
dismutase (Fridovich, I. J. Biol. Chem. 1998, 273, 24521-24528) and
peroxynitrite decomposition properties (Szabo, C. Mol. Med. 2002,
8, 571-580) relative to the 3-pyridyl and 4-pyridyl isomers and
high potency in animal models of inflammatory disease. The
2-pyridyl isomers also offer potential synthetic access to chiral
metalloporphyrin scaffolds for use as water-soluble oxidation
catalysts and hosts for chiral recognition.
[0026] Structures of Macrocyclic Compounds and Metal Complexes
[0027] Compounds of the invention include substituted 2-pyridyl
porphyrins, where the metal and ligands are absent. Compounds of
the invention also include metal complexes. The invention also
includes equivalents of the general formula set forth above for the
compounds, as well as the intermediates of the compounds that have
the same general properties as these compounds. Also included are
analogs of the compounds, e.g., compounds wherein one or more of
the various R.sub.1, R.sub.2, R.sub.3, and R.sub.4 groups are
simple variations of the substituents as defined therein, or
substituents which are a higher alkyl group than that
indicated.
[0028] Accordingly, one aspect the invention provides a novel
substituted porphyrin compound falling within formula I:
##STR00007##
[0029] R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are selected from
CH.sub.2C(O)NR.sub.5R.sub.6 and (CH.sub.2CH.sub.2O).sub.tCH.sub.3,
wherein t is 1, 2, 4, 5, 6, 7, 8, 9, or 10, and the remaining
R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are hydrogen. R.sub.5 and
R.sub.6 include, independently, H, alkyl, cycloalkyl, aralkyl, one
or more linear, dendritic or branched polyethers, such as
polyalkylene glycols (e.g., polyethylene glycol (PEG) moieties),
linear, dendritic or branched polycarboxylic acids, amides,
phosphates, phosphonic acids, sulfonic acids, amines, steroids,
amino acids, oligosaccharides, or peptides.
[0030] A "dendritic polymer" is a polymer exhibiting regular
dendritic branching i.e. branching like a tree. It can be formed by
the sequential or generational addition of branched layers to or
from a core. The term dendritic polymer encompasses "dendrimers",
which include a core, at least one interior branched layer, and a
surface branched layer (see, e.g., Petar et al., Pages 641-645 in:
Chem. in Britain, (August 1994). A "dendron" is a species of
dendrimer having branches emanating from a focal point which is or
can be joined to a core, either directly or through a linking
moiety to form a dendrimer. Many dendrimers comprise two or more
dendrons joined to a common core. However, the term dendrimer is
used broadly to encompass a single dendron.
[0031] Highly branched dendritic polymers are well known and are
discussed in, e.g., "Polymeric Materials Encyclopedia," Vol. 5
(1996), J. C. Salamone, Ed., CRC Press, New York, pp. 3049-3053.
Dendritic polymers have a non-linear architecture and are
intrinsically globular in shape. Discrete, stepwise synthetic
methods are used to prepare highly branched pure compounds, or
dendrimers. As discussed by Hawker and Devonport in "Step-Growth
Polymers for High-Performance Materials: New Synthetic Methods,"
Hedrick, J. L. and Labadie, J. W., Eds., Am. Chem. Soc.,
Washington, D.C., 1996, pp. 186-196, if the macromolecule has
highly regular branching which follows a strict geometric pattern,
it is a dendrimer. Dendrimers are typically monodisperse and are
prepared in a multi-step approach with purifications at each
stage.
[0032] The architecture of dendrimers is also discussed by Roovers
and Comanita in "Advances in Polymer Science," Vol. 142 (1999),
Roovers, J., Ed., Springer, New York, pp. 179-228. Dendrimers
consist of a core molecule which defines the center of symmetry of
the molecule, and branching layers. Tomalia, et al., in Angew.
Chem. Int. Ed. Eng., 29 (1990), 138-175 disclose "starburst"
dendrimers which consist of an initiator core and branching
groups.
[0033] Dendritic polymers include, but are not limited to,
symmetrical and unsymmetrical branching dendrimers, cascade
molecules, arborols (dumbbell shaped molecules in which a
hydrophobic spacer separates two hydrophilic end groups), dense
star polymers (symmetric, with branch arms of equal length, as
disclosed in U.S. Pat. No. 5,714,166), and the like.
[0034] In some embodiments, the compounds are hyperbranched.
Hyperbranched compounds result if the branching is random and
irregular and are therefore not monodisperse. As discussed by
Malmstroem, et al., in Macromolecules, 28 (1995), 1698-1703, a
hyperbranched material contains a mixture of linear and fully
branched repeating units and has a degree of branching of less than
unity. A preferred dendritic substance has a degree of branching of
unity. Even though not formed by regular sequential addition of
branched layers, hyperbranched polymers, e.g., hyperbranched
polyols, may be equivalent to a dendritic polymer where the
branching pattern exhibits a degree of regularity approaching that
of a dendrimer.
[0035] Peptidic dendrimer- and branched-peptides are disclosed in,
e.g., U.S. Pat. Nos. 6,379,679, 5,714,166 and 5,622,933. Branched
and hyperbranched polyetherimides are disclosed in, e.g., U.S. Pat.
No. 6,287,552. Enzymes modified by dendrimers are disclosed in,
e.g., U.S. Pat. No. 6,379,942.
[0036] One aspect of the invention includes a compound having the
Formula I:
##STR00008##
or a pharmaceutically acceptable base or acid addition salt,
hydrate, ester, solvate, prodrug, metabolite, or stereoisomer, or
mixtures thereof. In one embodiment, at least one of R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 is independently selected from the
group consisting of CH.sub.2C(O)NR.sub.5R.sub.6 and
(CH.sub.2CH.sub.2O).sub.tCH.sub.3 and the remaining R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 are hydrogen. t is 1, 2, 4, 5, 6, 7,
8, 9, or 10. R.sub.5 and R.sub.6 are selected from H,
CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2OCH.sub.2CH.sub.2
OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2COO.sup.-, (CH.sub.2).sub.n--X, (CH.sub.2).sub.n--Y,
(CH.sub.2).sub.nR.sub.9--X, (CH.sub.2).sub.nR.sub.9--Y,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, (OCH.sub.2CH.sub.2).sub.m--X,
(OCH.sub.2CH.sub.2).sub.m--Y, Y.sub.2--X, Y.sub.2C(Z.sub.1).sub.3,
further wherein: Z.sub.1 is CH.sub.2OCH.sub.2(CH.sub.2).sub.IX or
CH.sub.2OCH.sub.2(CH.sub.2).sub.nY;
(CH.sub.2).sub.nC(O)Y.sub.2C(Z.sub.2).sub.3, wherein: Z.sub.2 is
CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.4).sub.3 and Z.sub.4 is
CH.sub.2OCH.sub.2CH.sub.2X;
(CH.sub.2).sub.nC(O)--Y.sub.2--C(Z.sub.5).sub.3, wherein: Z.sub.5
is CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.6).sub.3 and Z.sub.6
is
CH.sub.2OCH.sub.2CH.sub.2C(O)O(CH.sub.2CH.sub.2O).sub.mCH.sub.2CH.sub.2O.-
sup.-; (CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.3,
(CH.sub.2).sub.nOCH.sub.2CH(CH.sub.2OH).sub.2,
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.2(CH.sub.3),
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2OH).sub.3].sub.3,
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2O[CH.sub.2CH.sub.2O-
].sub.mCH.sub.2CH.sub.2OX).sub.3].sub.3, CH.sub.2CONH--Y,
CH.sub.2CO--Y, CH.sub.2CO(CH.sub.2).sub.p--Y; alkyl, cycloalkyl,
and aralkyl. n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8,
9, and 10. m is an integer from 1 to 200. p is 1 or 2. X is COOH,
COOR', CONH.sub.2, CONHR', CONR'.sub.2, CO(CH.sub.2).sub.pR',
OPO.sub.3H.sub.2, PO.sub.3H.sub.2, SO.sub.3H, NH.sub.2, NR'.sub.2,
or NR'.sub.3.sup.+, a steroid, an amino acid, an oligosaccharide, a
peptide, or a polycarboxylic acid. R' is alkyl,
CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3, (CH.sub.2).sub.n--X,
(CH.sub.2).sub.n--Y, (CH.sub.2).sub.nAr--X, (CH.sub.2).sub.nAr--Y,
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CO.sub.2CH.sub.2CH.sub.3, (OCH.sub.2CH.sub.2).sub.m--X,
(OCH.sub.2CH.sub.2).sub.mY, Y.sub.2--X, Y.sub.2C(Z.sub.1).sub.3,
further wherein: Z.sub.1 is CH.sub.2OCH.sub.2(CH.sub.2).sub.nX or
CH.sub.2OCH.sub.2(CH.sub.2).sub.nN;
(CH.sub.2).sub.nC(O)Y.sub.2C(Z.sub.2).sub.3, wherein: Z.sub.2 is
CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.4).sub.3 and Z.sub.4 is
CH.sub.2OCH.sub.2CH.sub.2X;
(CH.sub.2).sub.nC(O)--Y.sub.2--C(Z.sub.5).sub.3, wherein: Z.sub.5
is CH.sub.2OCH.sub.2CH.sub.2C(O)Y.sub.2C(Z.sub.6).sub.3 and Z.sub.6
is
CH.sub.2OCH.sub.2CH.sub.2C(O)O(CH.sub.2CH.sub.2O).sub.mCH.sub.2CH.sub.2O.-
sup.-; (CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.3,
(CH.sub.2).sub.nOCH.sub.2CH(CH.sub.2OH).sub.2,
(CH.sub.2).sub.nOCH.sub.2C(CH.sub.2OH).sub.2(CH.sub.3),
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2OH).sub.3].sub.3,
(CH.sub.2).sub.nOCH.sub.2C[CH.sub.2OCH.sub.2C(CH.sub.2O[CH.sub.2CH.sub.2O-
].sub.mCH.sub.2CH.sub.2OX).sub.3].sub.3, CH.sub.2CONH--Y,
CH.sub.2CO--Y, and CH.sub.2CO(CH.sub.2).sub.p--Y.
[0037] Y is OH or (OCH.sub.2CH.sub.2).sub.m--W.sub.1 or
(CH.sub.2CH.sub.2).sub.m--W.sub.2; where W.sub.1 is OH, or
(OCH.sub.2CH.sub.2).sub.mOH and W.sub.2 is OR''. R'' is an alkyl
group. Y.sub.2 is selected from the group consisting of
(CH.sub.2).sub.nO, (CH.sub.2).sub.nNH, and (CH.sub.2).sub.nS,
CH.sub.2CONH, CH.sub.2COO, or CH.sub.2CO(CH.sub.2).sub.p. R.sub.9
is substituted phenyl, unsubstituted phenyl, substituted napthyl,
or unsubstituted naphthyl. L.sub.1 and L.sub.2 are, independently,
absent, halide, oxo, OH.sub.2, hydroxo, CN, OPO.sub.3H or alcohol;
and M is absent, Mn or Fe. In one embodiment, R.sub.5 and R.sub.6
are not both alkyl.
[0038] In one embodiment, at least one of R.sub.1, R.sub.2,
R.sub.3, or R.sub.4 is CH.sub.2C(O)NR.sub.5R.sub.6. In another
embodiment, at least two of R.sub.1, R.sub.2, R.sub.3, or
R.sub.4CH.sub.2C(O)NR.sub.5R.sub.6. In another embodiment, at least
three of R.sub.1, R.sub.2, R.sub.3, or R.sub.4 are
CH.sub.2C(O)NR.sub.5R.sub.6. In another embodiment, R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 are each
CH.sub.2C(O)NR.sub.5R.sub.6.
[0039] In one embodiment, at least one of R.sub.1, R.sub.2,
R.sub.3, or R.sub.4 is CH.sub.2C(O)NR.sub.5R.sub.6 and the
remaining R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are H. In another
embodiment, at least two of R.sub.1, R.sub.2, R.sub.3, or R.sub.4
CH.sub.2C(O)NR.sub.5R.sub.6 and the remaining R.sub.1, R.sub.2,
R.sub.3, and R.sub.4 are H In another embodiment, at least three of
R.sub.1, R.sub.2, R.sub.3, or R.sub.4 are
CH.sub.2C(O)NR.sub.5R.sub.6 and the remaining R.sub.1, R.sub.2,
R.sub.3, and R.sub.4 are H
[0040] In one embodiment, M is a metal. In another embodiment, M is
tin, silicon, germanium, copper, iron, cobalt, zinc, nickel, or
manganese. In one embodiment, M is Mn, Fe, or Zn. In another
embodiment, M is Mn or Fe. In another embodiment, M is Mn. In
another embodiment, M is Fe. In another embodiment, M is Zn. In
another embodiment, M is absent.
[0041] In one embodiment, one of R.sub.5 or R.sub.6 is H. In one
embodiment, one of R.sub.5 or R.sub.6 is selected from aralkyl,
alkyl, cycloalkyl, substituted cycloalkyl, and
CH.sub.2CH.sub.2OCH.sub.3. In one embodiment, one of R.sub.5 or
R.sub.6 is selected from aralkyl, alkyl, cycloalkyl, substituted
cycloalkyl, and CH.sub.2CH.sub.2OCH.sub.3 and the remaining R.sub.5
or R.sub.6 is H.
[0042] In one embodiment, one of R.sub.5 or R.sub.6 is aralkyl. In
one embodiment, one of R.sub.5 or R.sub.6 is aralkyl and the other
is H. In another embodiment, aralkyl is
(CR.sub.7R.sub.8).sub.n--R.sub.9, wherein R.sub.7 and R.sub.8 are,
independently, selected from H, alkyl, OH, and halogen, and s is 1,
2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, one of R.sub.7 or
R.sub.8 is H. In another embodiment, one of R.sub.7 or R.sub.8 is
alkyl. In one embodiment, one of R.sub.7 or R.sub.8 is methyl. In
one embodiment, one of R.sub.7 or R.sub.8 is H and the other one of
R.sub.7 or R.sub.8 is alkyl. In one embodiment, s is 1. In another
embodiment, s is 2. In another embodiment, s is 3. In another
embodiment, s is 4. In another embodiment, s is 5. In one
embodiment, R.sub.9 is phenyl. In another embodiment, R.sub.9 is
substituted phenyl. In one embodiment, aralkyl is racemic
##STR00009##
In another embodiment, aralkyl is
##STR00010##
where the chiral center is in the R configuration. In another
embodiment, aralkyl is
##STR00011##
where the chiral center is in the S configuration.
[0043] In one embodiment, one of R.sub.5 or R.sub.6 is selected
from alkyl, cycloalkyl, or substituted cycloalkyl. In another
embodiment, one of R.sub.5 or R.sub.6 is selected from alkyl,
cycloalkyl, or substituted cycloalkyl and the remaining R.sub.5 or
R.sub.6 is H. In one embodiment, cycloalkyl or substituted
cycloalkyl is a bicyclic ring system. In another embodiment, the
bicyclic ring system is bicycle[2.2.1]heptane. In another
embodiment, the bicyclic ring system is
1,7,7-trimethylbicyclo[2.2.1]heptane.
[0044] In one embodiment, one of R.sub.5 or R.sub.6 is a linear,
dendritic, or branched polyether e.g., a polyethylene glycol (PEG)
moiety). In another embodiment, one of R.sub.5 or R.sub.6 is a
linear, dendritic, or branched polyether e.g., a polyethylene
glycol (PEG) moiety) and the other R.sub.5 or R.sub.6 is H. In one
embodiment, one of R.sub.5 or R.sub.6 is CH.sub.2CH.sub.2OCH.sub.3.
In another embodiment, one of R.sub.5 or R.sub.6 is
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3. In another embodiment,
one of R.sub.5 or R.sub.6 is
CH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3.
[0045] In one embodiment, at least one of R.sub.1, R.sub.2,
R.sub.3, or R.sub.4 is (CH.sub.2CH.sub.2O).sub.tCH.sub.3. In
another embodiment, at least two of R.sub.1, R.sub.2, R.sub.3, or
R.sub.4 are (CH.sub.2CH.sub.2O).sub.tCH.sub.3. In another
embodiment, at least three of R.sub.1, R.sub.2, R.sub.3, or R.sub.4
are (CH.sub.2CH.sub.2O).sub.tCH.sub.3. In another embodiment,
R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are
(CH.sub.2CH.sub.2O).sub.tCH.sub.3.
[0046] In one embodiment, at least one of R.sub.1, R.sub.2,
R.sub.3, or R.sub.4 is (CH.sub.2CH.sub.2O).sub.tCH.sub.3 and the
remaining R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is H. In another
embodiment, at least two of R.sub.1, R.sub.2, R.sub.3, or R.sub.4
are (CH.sub.2CH.sub.2O).sub.tCH.sub.3 and the remaining R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 is H. In another embodiment, at least
three of R.sub.1, R.sub.2, R.sub.3, or R.sub.4 are
(CH.sub.2CH.sub.2O).sub.tCH.sub.3 and the remaining R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 is H.
[0047] In one embodiment, t is 1. In another embodiment, t is 2. In
another embodiment, t is 4. In another embodiment, t is 5. In
another embodiment, t is 6. In another embodiment, t is 7. In
another embodiment, t is 8. In another embodiment, t is 9. In
another embodiment, t is 10.
[0048] In one embodiment, the compound is a mixture of
atropoisomers .alpha..alpha..alpha..alpha.,
.alpha..alpha..alpha..beta., .alpha..alpha..beta..beta., and
.alpha..beta..alpha..beta.. In another embodiment, the compound is
an .alpha..alpha..beta..beta. atropisomer.
[0049] In another embodiment, the compound is selected from
##STR00012## ##STR00013##
[0050] wherein L.sub.1 and L.sub.2 are, independently, absent,
halide, oxo, OH.sub.2, hydroxo, CN, OPO.sub.3H or alcohol; and M is
absent, Mn or Fe.
[0051] One aspect of the invention includes a pharmaceutical
composition comprising the compound of formula I and a
pharmaceutically acceptable carrier.
[0052] Another aspect of the invention includes a method of
lowering peroxynitrite levels in a cell or tissue, the method
comprising contacting said cell or tissue with a compound of
formula I in an amount sufficient to lower peroxynitrite levels in
said cell or tissue. In one embodiment, at least one of R.sub.1,
R.sub.2, R.sub.3, or R.sub.4 is CH.sub.2C(O)NR.sub.5R.sub.6. In
another embodiment, at least two of R.sub.1, R.sub.2, R.sub.3, or
R.sub.4 are CH.sub.2C(O)NR.sub.5R.sub.6. In another embodiment, at
least three of R.sub.1, R.sub.2, R.sub.3, or R.sub.4 are
CH.sub.2C(O)NR.sub.5R.sub.6. In another embodiment, R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 are CH.sub.2C(O)NR.sub.5R.sub.6. In
another embodiment, at least one of R.sub.1, R.sub.2, R.sub.3, or
R.sub.4 is (CH.sub.2CH.sub.2O).sub.tCH.sub.3. In another
embodiment, at least two of R.sub.1, R.sub.2, R.sub.3, or R.sub.4
are (CH.sub.2CH.sub.2O).sub.tCH.sub.3. In another embodiment, at
least three of R.sub.1, R.sub.2, R.sub.3, or R.sub.4 are
(CH.sub.2CH.sub.2O).sub.tCH.sub.3. In another embodiment, R.sub.1,
R.sub.2, R.sub.3, and R.sub.4 are
(CH.sub.2CH.sub.2O).sub.tCH.sub.3.
[0053] Another aspect of the invention includes a method of
treating or inhibiting the development of a pathology associated
with peroxynitrite damage in a subject, the method comprising
administering to a subject in need thereof a therapeutically
effective amount of the compound of Formula I. In one embodiment,
the pathology is selected from the group consisting of Alzheimer's
disease, amyotrophic lateral sclerosis, stroke, AIDS dementia,
Huntington's disease, atherosclerosis, inflammation, arthritis,
neurodegeneration, sepsis, autoimmune diseases, cancer,
ischemia-reperfusion injury, septic shock, diabetes, diabetic
vascular complications, diabetic cardiomyopathy, diabetic
neuropathy, hyperglycemia, pathophysiological conditions of the
heart, acute myocardial infarction, chronic ischemic heart failure,
doxorubicin-induced cardiac disfunction, oxidative stress,
obliterative bronchiolitis, colitis, vascular dysfunction,
myocardial dysfunction, myocardial necrosis, and chronic graft. In
another embodiment, the subject is a human.
[0054] In one embodiment, the compounds are provided in association
with suitable ligands (L.sub.1 and L.sub.2) and/or charge
neutralizing anions. L.sub.1 and L.sub.2 can be the same or
different, and one or more may be absent. Ligands and charge
neutralizing anions can be derived from any monodentate or
polydentate coordinating ligand or ligand system or the
corresponding anion thereof. They are independently selected from
the group consisting of halide, oxo, aquo, hydroxo, alcohol,
phenol, dioxygen, peroxo, hydroperoxo, alkylperoxo, arylperoxo,
ammonia, alkylamino, arylamino, heterocycloalkyl amino,
heterocycloaryl, amino, amine oxides, hydrazine, alkyl hydrazine,
aryl hydrazine, nitric oxide, cyanide, cyanate, thiocyanate,
isocyanate, isothiocyanate, alkyl nitrile, aryl nitrile, alkyl
isonitrile, aryl isozutrile, nitrate, nitrite, azido, alkyl
sulfonic acid, aryl sulfonic acid, alkyl sulfoxide, aryl sulfoxide,
alkyl aryl sulfoxide, alkyl sulfenic acid, aryl sulfenic acid,
alkyl sulfinic acid, aryl sulfinic acid, alkyl thiol carboxylic
acid, aryl thiol carboxylic acid, alkyl thiol thiocarboxylic acid,
aryl thiol thiocarboxylic acid, alkyl carboxylic acid, aryl
carboxylic acid, urea, alkyl urea, aryl urea, alkyl aryl urea,
thiourea, alkyl thiourea, aryl thiourea, alkyl aryl thiourea,
sulfate, sulfite, bisulfate, bisulfite, thiosulfate, thiosulfite,
hydrosulfite, alkyl phosphine, aryl phosphine, alkyl phosphine
oxide, aryl phosphine oxide, alkyl aryl phosphine oxide, alkyl
phosphine sulfide, aryl phosphine sulfide, alkyl aryl phosphine
sulfide, alkyl phosphonic acid, aryl phosphonic acid, alkyl
phosphinic acid, aryl phosphinic acid, alkyl phosphinous acid, aryl
phosphinous acid, phosphate, thiophosphate, phosphite,
pyrophosphite, triphosphate, hydrogen phosphate, dihydrogen
phosphate, alkyl guanidino, aryl guanidino, alkyl aryl guanidino,
alkyl carbamate, aryl carbamate, alkyl aryl carbamate, alkyl
thiocarbamate, aryl thiocarbamate, alkyl aryl thiocarbamate, alkyl
ditbiocarbamate, aryl dithiocarbamate, alkyl aryl dithiocarbamate,
bicarbonate, carbonate, perchlorate, chlorate, chlorite,
hypochlorite, perbromate, bromate, bromite, hypobromite,
tetrahalomanganate, tetrafluoroborate, hexafluorophosphate,
hexafluoroanitmonate, hypophosphite, iodate, periodate, metaborate,
tetraaryl borate, tetra alkyl borate, tartrate, salicylate,
succinate, citrate, ascorbate, saccharinate, amino acid, hydroxamic
acid, thiotosylate, and anions of ion exchange resins, or systems;
with the proviso that when the charge neutralizing complex has a
net positive charge, then D is a negatively charged counter ion or
when the charge neutralizing complex has net negative charge then D
is a counter ion selected from a group consisting of alkaline and
alkaline earth cations, organic cations such as alkyl or alkylaryl
ammonium cations.
[0055] Preferred ligands include halide, oxo, aquo, hydroxo and
alcohol. Preferred anionic counterions include halide ions. Halide
ions include fluoro, chloro, bromo or iodo ions. Ligands and
counterions may be the same or different. For example, a metallic
complex may have one or two chloro axial ligands and 1, 2, 3, or 4
chloride ions as charge neutralizing anions.
[0056] As utilized herein, the term "alkyl", alone or in
combination, means a straight-chain or branched-chain alkyl radical
containing from 1 to about 22 carbon atoms, preferably from about 1
to about 18 carbon atoms, and most preferably from about 1 to about
12 carbon atoms. Examples of such radicals include, but are not
limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl,
decyl, dodecyl, tetradecyl, hexadecyl, octadecyl and eicosyl. Lower
alkyl refers to a straight-chain or branched-chain alkyl radical
containing 1, 2, 3, 4, 5, or 6 carbon atoms.
[0057] The term "cycloalkyl", alone or in combination means a
cycloalkyl group containing 3 4, 5, 6, 7, 8, 9, or 10 atoms. In one
embodiment, cycloalkyl contains 3, 4, 5, 6, 7, or 8 atoms, and in
another embodiment, cycloalkyl contains 3, 4, 5, or 6 atoms.
Examples of such cycloalkyl groups include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl, and perhydronaphthyl.
[0058] The term "cycloalkenyl", alone or in combination, means a
cycloalkyl group having one or more double bonds. Examples include,
but are not limited to, cyclopentenyl, cyclohexenyl, cyclooctenyl,
cyclopentadienyl, and cyclooctadienyl.
[0059] The terms cycloalkyl and cycloalkenyl include "bicyclic ring
systems" which means polycyclic ring systems where rings share
adjacent carbons and the rings are said to be fused or annelated.
Bicyclic ring systems are characterized by two carbon atoms, the
bridgehead carbons, being shared by two rings.
##STR00014##
[0060] Examples of bicyclic ring systems include for example,
##STR00015##
[0061] Bicyclic ring systems can be optionally substituted with one
or more substituents selected from alkyl, cycloalkyl, cycloalkenyl,
aryl, heterocycle, alkoxyaryl, alkaryl, alkoxy, halogen, hydroxy,
amine, cyano, nitro, alkylthio, phenoxy, ether, trifluoromethyl and
the like. Examples of substituted bicyclic ring systems include
camphor, 1,7,7-trimethylbicyclo[2.2.1]heptane, .beta.-cadinene, and
steroids such as e.g., cholesterol, cholic acid, cortisone,
testosterone, estradiol, and progesterone.
[0062] The term "aryl" or "Ar", alone or in combination, means a
phenyl or naphthyl radical which optionally carries one or more
substituents selected from alkyl, cycloalkyl, cycloalkenyl, aryl,
heterocycle, alkoxyaryl, alkaryl, alkoxy, halogen, hydroxy, amine,
cyano, nitro, alkylthio, phenoxy, ether, trifluoromethyl and the
like, such as phenyl, p-tolyl, 4-methoxy-phenyl,
4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl,
4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like.
[0063] The term "aralkyl", alone or in combination, means an alkyl
or cycloalkyl radical as defined herein in which one hydrogen atom
is replaced by an aryl radical as defined herein, such as benzyl,
2-phenylethyl, and the like.
[0064] The term "heterocyclic" or "heterocycloalkyl" group means
ring structures containing at least one other kind of atom, in
addition to carbon, in the ring. The most common of the other kinds
of atoms include nitrogen, oxygen and sulfur. Heterocyclic systems
include 3, 4, 5, 6, 7 and 8-membered monocyclic ring systems. A
heterocyclic group can have one or more carbon-carbon double bonds
or carbon-heteroatom double bonds in the ring so long as the ring
is not rendered aromatic by their presence. Examples of
heterocyclic groups include, but are not limited to, aziridineyl,
pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl,
piperazino, morpholinyl, morpholino, thiomorpholinyl,
thiomorpholino, tetrahydrofuranyl, tetrahydrothiofuranyl,
tetrahydropyranyl, and pyranyl. A heterocyclic group can be
unsubstituted or substituted with one or more suitable
substituents.
[0065] The terms "aryl heterocycles", "heteroaryls" or
"heteroaromatics" refer to those aryl groups having heteroatoms in
the ring structure. The aromatic ring can be substituted at one or
more ring positions with substituents for example, alkyl, halogen,
hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy,
alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl,
alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl,
alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl,
alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate,
phosphonato, phosphinato, cyano, amino (including alkylamino,
dialkylamino, arylamino, diarylamino, and alkylarylamino),
acylamino (including alkylcarbonylamino, arylcarbonylamino,
carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio,
arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato,
sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido,
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
Aryl groups can also be fused or bridged with alicyclic or
heterocyclic rings, which are not aromatic so as to form a
multicyclic system (e.g., tetralin, methylenedioxyphenyl).
[0066] The term "ester" includes compounds and moieties which
contain a carbon bound to an oxygen atom which is bonded to the
carbon of a carbonyl group. The term "ester" includes alkoxycarboxy
groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,
butoxycarbonyl, pentoxycarbonyl, etc.
[0067] The term "hydroxy" or "hydroxyl" includes groups with an
--OH or -O.sup.-.
[0068] The term "halogen" includes fluorine, bromine, chlorine,
iodine, etc. The term "perhalogenated" generally refers to a moiety
wherein all hydrogens are replaced by halogen atoms.
[0069] In the present specification, the structural formula of the
compound represents a certain isomer for convenience in some cases,
but the present invention includes all isomers such as geometrical
isomer, optical isomer based on an asymmetrical carbon,
stereoisomer, tautomer and the like which occur structurally and an
isomer mixture and is not limited to the description of the formula
for convenience, and may be any one of isomer or a mixture.
Therefore, an asymmetrical carbon atom may be present in the
molecule and an optically active compound and a racemic compound
may be present in the present compound, but the present invention
is not limited to them and includes any one. In addition, a crystal
polymorphism may be present but is not limiting, but any crystal
form may be single or a crystal form mixture, or an anhydride or
hydrate. Further, so-called metabolite which is produced by
degradation of the present compound in vivo is included in the
scope of the present invention.
[0070] It will be noted that the structure of some of the compounds
of the invention include asymmetric (chiral) carbon atoms. It is to
be understood accordingly that the isomers arising from such
asymmetry are included within the scope of the invention, unless
indicated otherwise. Such isomers can be obtained in substantially
pure form by classical separation techniques and by
stereochemically controlled synthesis. The compounds of this
invention may exist in stereoisomeric form, therefore can be
produced as individual stereoisomers or as mixtures.
[0071] "Isomerism" means compounds that have identical molecular
formulae but that differ in the nature or the sequence of bonding
of their atoms or in the arrangement of their atoms in space.
Isomers that differ in the arrangement of their atoms in space are
termed "stereoisomers". Stereoisomers that are not mirror images of
one another are termed "diastereoisomers", and stereoisomers that
are non-superimposable mirror images are termed "enantiomers", or
sometimes optical isomers. A carbon atom bonded to four
non-identical substituents is termed a "chiral center".
[0072] "Chiral isomer" means a compound with at least one chiral
center. It has two enantiomeric forms of opposite chirality and may
exist either as an individual enantiomer or as a mixture of
enantiomers. A mixture containing equal amounts of individual
enantiomeric forms of opposite chirality is termed a "racemic
mixture". A compound that has more than one chiral center has
2.sup.n-1 enantiomeric pairs, where n is the number of chiral
centers. Compounds with more than one chiral center may exist as
either an individual diastereomer or as a mixture of diastereomers,
termed a "diastereomeric mixture". When one chiral center is
present, a stereoisomer may be characterized by the absolute
configuration (R or S) of that chiral center. Absolute
configuration refers to the arrangement in space of the
substituents attached to the chiral center. The substituents
attached to the chiral center under consideration are ranked in
accordance with the Sequence Rule of Calm, Ingold and Prelog. (Calm
et al, Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et
al., Angew. Chem. 1966, 78, 413; Calm and Ingold, J. Chem. Soc.
1951 (London), 612; Calm et al., Experientia 1956, 12, 81; Calm,
J., Chem. Educ. 1964, 41, 116).
[0073] "Geometric Isomers" means diastereomers that owe their
existence to hindered rotation about double bonds. These
configurations are differentiated in their names by the prefixes
cis and trans, or Z and E, which indicate that the groups are on
the same or opposite side of the double bond in the molecule
according to the Cahn-Ingold-Prelog rules.
[0074] Further, the structures and other compounds discussed in
this application include all atropic isomers or atropisomers
(rotational isomers) thereof. "Atropic isomers" are a type of
stereoisomer in which the atoms of isomers are arranged differently
in space. Atropic isomers owe their existence to a restricted
rotation caused by hindrance of rotation of large groups about a
central bond. Such atropic isomers typically exist as a mixture,
however as a result of recent advances in chromatography
techniques, it has been possible to separate mixtures of two
atropic isomers in select cases. Below is an illustration of
atropisomers of
meso-tetrakis-(N-alkylpyridinium-2-yl)-porphyrin.
##STR00016##
[0075] The terms "crystal polymorphs" or "polymorphs" or "crystal
forms" means crystal structures in which a compound (or salt or
solvate thereof) can crystallize in different crystal packing
arrangements, all of which have the same elemental composition.
Different crystal forms usually have different X-ray diffraction
patterns, infrared spectral, melting points, density hardness,
crystal shape, optical and electrical properties, stability and
solubility. Recrystallization solvent, rate of crystallization,
storage temperature, and other factors may cause one crystal form
to dominate. Crystal polymorphs of the compounds can be prepared by
crystallization under different conditions. For example, using
different solvents or different solvent mixtures for
recrystallization; crystallization at different temperatures;
various modes of cooling, ranging from very fast to very slow
cooling during crystallization, and the like. Polymorphs are also
obtained by heating or melting the disclosed compounds followed by
gradual or fast cooling. The presence of polymorphs is determined
by solid probe nuclear magnetic resonance spectroscopy, infrared
spectroscopy, differential scanning calorimetry, powder X-ray
diffraction, and other techniques known to one skilled in the
art.
[0076] Additionally, the compounds of the present invention, for
example, the salts of the compounds, can exist in either the
hydrated or unhydrated (anhydrous) form or as solvates with other
solvent molecules. Non-limiting examples of hydrates include
monohydrates, dihydrates, etc. Non-limiting examples of solvates
include ethanol solvates, acetone solvates, etc.
[0077] Some compounds of the present invention can exist in a
tautomeric form which are also intended to be encompassed within
the scope of the present invention.
[0078] The compounds, salts and prodrugs of the present invention
can exist in several tautomeric forms, including the enol and imine
form, and the keto and enamine form and geometric isomers and
mixtures thereof. All such tautomeric forms are included within the
scope of the present invention. Tautomers exist as mixtures of a
tautomeric set in solution. In solid form, usually one tautomer
predominates. Even though one tautomer may be described, the
present invention includes all tautomers of the present
compounds
[0079] A tautomer is one of two or more structural isomers that
exist in equilibrium and are readily converted from one isomeric
form to another. This reaction results in the formal migration of a
hydrogen atom accompanied by a switch of adjacent conjugated double
bonds. In solutions where tautomerization is possible, a chemical
equilibrium of the tautomers will be reached. The exact ratio of
the tautomers depends on several factors, including temperature,
solvent, and pH. The concept of tautomers that are interconvertable
by tautomerizations is called tautomerism.
[0080] Of the various types of tautomerism that are possible, two
are commonly observed. In keto-enol tautomerism a simultaneous
shift of electrons and a hydrogen atom occurs. Ring-chain
tautomerism, is exhibited by glucose. It arises as a result of the
aldehyde group (--CHO) in a sugar chain molecule reacting with one
of the hydroxy groups (--OH) in the same molecule to give it a
cyclic (ring-shaped) form.
[0081] Tautomerizations are catalyzed by: Base: 1. deprotonation;
2. formation of a delocalized anion (e.g., an enolate); 3.
protonation at a different position of the anion; Acid: 1.
protonation; 2. formation of a delocalized cation; 3. deprotonation
at a different position adjacent to the cation.
[0082] Common tautomeric pairs are: ketone-enol, amide-nitrile,
lactam-lactim, amide-imidic acid tautomerism in heterocyclic rings
(e.g., in the nucleobases guanine, thymine, and cytosine),
amine-enamine and enamine-enamine. Examples include:
##STR00017##
[0083] "Solvates" means solvent addition forms that contain either
stoichiometric or non stoichiometric amounts of solvent. Some
compounds have a tendency to trap a fixed molar ratio of solvent
molecules in the crystalline solid state, thus forming a solvate.
If the solvent is water the solvate formed is a hydrate, when the
solvent is alcohol, the solvate formed is an alcoholate. Hydrates
are formed by the combination of one or more molecules of water
with one of the substances in which the water retains its molecular
state as H.sub.2O, such combination being able to form one or more
hydrate.
[0084] The term "2-PyP" refers to a porphyrin substituted with
2-pyridyl substituents e.g.,
##STR00018##
[0085] The term "metal(s)" refers to any atom of the Periodic Table
having the properties of a metal. These include preferably all
transition metals, actinides and lanthanides. More preferably tin,
silicon, germanium, copper, iron, cobalt, zinc, nickel or manganese
are used. See Porphyrins and Metalloporphyrins by K. M. Smith,
Elsevier/North-Holland Biochemical Press (1976), which is
incorporated herein in its entirety by reference. "Metal salt"
refers to an organic or inorganic salt used to treat a
dihydro-porphyrin compound to produce the corresponding metal
porphyrin compound. Acetates and propionates are preferred.
[0086] The term "pharmacologically effective amount" as used herein
means an amount that slows or prevents the progression of the
targeted disease or pathology. It is preferable that the slowing or
prevention not be accompanied by a toxic effect that offsets the
medical value of slowing or preventing the progression of the
targeted disease or pathology.
[0087] The "pharmaceutically acceptable carrier" must be
"acceptable" in the sense of being compatible with the compounds or
compositions of the invention and not deleterious to the subject to
be treated. Preferably, the carrier is also capable of stabilizing
the compound or composition.
[0088] The compounds of the invention are capable of further
forming salts. All of these forms are also contemplated within the
scope of the claimed invention.
[0089] "Pharmaceutically acceptable salt" of a compound means a
salt that is pharmaceutically acceptable and that possesses the
desired pharmacological activity of the parent compound.
[0090] As used herein, "pharmaceutically acceptable salts" refer to
derivatives of the disclosed compounds wherein the parent compound
is modified by making acid or base salts thereof. Examples of
pharmaceutically acceptable salts include, but are not limited to,
mineral or organic acid salts of basic residues such as amines,
alkali or organic salts of acidic residues such as carboxylic
acids, and the like. The pharmaceutically acceptable salts include
the conventional non-toxic salts or the quaternary ammonium salts
of the parent compound formed, for example, from non-toxic
inorganic or organic acids. For example, such conventional
non-toxic salts include, but are not limited to, those derived from
inorganic and organic acids selected from 2-acetoxybenzoic,
2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic,
benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic,
1,2-ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic,
glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic,
hydrobromic, hydrochloric, hydroiodic, hydroxymaleic,
hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic,
maleic, malic, mandelic, methane sulfonic, napsylic, nitric,
oxalic, pamoic, pantothenic, phenylacetic, phosphoric,
polygalacturonic, propionic, salicyclic, stearic, subacetic,
succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, toluene
sulfonic, and the commonly occurring amine acids, e.g., glycine,
alanine, phenylalanine, arginine, etc.
[0091] Other examples include hexanoic acid, cyclopentane propionic
acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid,
cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic
acid, 4-toluenesulfonic acid, camphorsulfonic acid,
4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid,
3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic
acid, muconic acid, and the like. The invention also encompasses
salts formed when an acidic proton present in the parent compound
either is replaced by a metal ion, e.g., an alkali metal ion, an
alkaline earth ion, or an aluminum ion; or coordinates with an
organic base such as ethanolamine, diethanolamine, triethanolamine,
tromethamine, N-methylglucamine, and the like.
[0092] It should be understood that all references to
pharmaceutically acceptable salts include solvent addition forms
(solvates) or crystal forms (polymorphs) as defined herein, of the
same salt.
[0093] The pharmaceutically acceptable salts of the present
invention can be formed from a parent compound that contains a
basic or acidic moiety by conventional chemical methods. Generally,
such salts can be prepared by reacting the free acid or base forms
of these compounds with a stoichiometric amount of the appropriate
base or acid in water or in an organic solvent, or in a mixture of
the two; generally, non-aqueous media like ether, ethyl acetate,
ethanol, isopropanol, or acetonitrile are used.
[0094] The number of atoms protonated and counterions associated
with the salt can be controlled and depends on the number of
acidic/basic atoms in the parent compound and amount of acid which
is used to treat the parent compound. In one embodiment of the
invention, the monohydrochloride salt of the parent compound is
formed upon treatment with hydrochloric acid. In another
embodiment, the dihydrochloride salt of the parent compound is
formed upon treatment with hydrochloric acid.
[0095] Lists of suitable salts are found in Remington's
Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990).
For example, salts can include, but are not limited to, the
hydrochloride and acetate salts of the aliphatic amine-containing,
hydroxyl amine-containing, and imine-containing compounds of the
present invention.
[0096] The compounds of the present invention can also be prepared
as esters, for example pharmaceutically acceptable esters. For
example a carboxylic acid function group in a compound can be
converted to its corresponding ester, e.g., a methyl, ethyl, or
other ester. Also, an alcohol group in a compound can be converted
to its corresponding ester, e.g., an acetate, propionate, or other
ester.
[0097] The compounds of the present invention can also be prepared
as prodrugs, for example pharmaceutically acceptable prodrugs. The
terms "pro-drug" and "prodrug" are used interchangeably herein and
refer to any compound which releases an active parent drug in vivo.
Since prodrugs are known to enhance numerous desirable qualities of
pharmaceuticals (e.g., solubility, bioavailability, manufacturing,
etc.) the compounds of the present invention can be delivered in
prodrug form. Thus, the present invention is intended to cover
prodrugs of the presently claimed compounds, methods of delivering
the same and compositions containing the same. "Prodrugs" are
intended to include any covalently bonded carriers that release an
active parent drug of the present invention in vivo when such
prodrug is administered to a subject. Prodrugs the present
invention are prepared by modifying functional groups present in
the compound in such a way that the modifications are cleaved,
either in routine manipulation or in vivo, to the parent compound.
Prodrugs include compounds of the present invention wherein a
hydroxy, amino, sulfhydryl, carboxy, or carbonyl group is bonded to
any group that, may be cleaved in vivo to form a free hydroxyl,
free amino, free sulfhydryl, free carboxy or free carbonyl group,
respectively.
[0098] Examples of prodrugs include, but are not limited to, esters
(e.g., acetate, dialkylaminoacetates, formates, phosphates,
sulfates, and benzoate derivatives) and carbamates (e.g.,
N,N-dimethylaminocarbonyl) of hydroxy functional groups, esters
groups (e.g., ethyl esters, morpholinoethanol esters) of carboxyl
functional groups, N-acyl derivatives (e.g., N-acetyl) N-Mannich
bases, Schiff bases and enaminones of amino functional groups,
oximes, acetals, ketals and enol esters of ketone and aldehyde
functional groups in compounds of Formulae I, and the like, See
Bundegaard, H. "Design of Prodrugs" p1-92, Elesevier, New
York-Oxford (1985).
[0099] In one embodiment, the compound is based on a porphyrin
structure. As used herein, the term "porphyrin" includes compounds
prior to a metal atom being inserted into the ring system, as well
as molecular systems in which compounds are attached to the metal.
The substituents, as well as the overall porphyrin structure, can
be neutral, positively charged, or negatively charged.
Synthesis of Peroxynitrite Decomposition Catalysts
[0100] In various embodiments, the macrocyclic compounds of the
invention are provided as a metallic complex. The metallic
complexes can be, e.g., porphyrin-iron, porphyrin-manganese, or
porphyrin-zinc complexes.
[0101] Starting porphyrins can be prepared according to methods
well known in the art. The methods can include, for example, those
described in WO95/31197, Campestrini and Meunier, Inorg. Chem. 31,
1999-2006, (1992); Robert et al., Inorg. Chem. 30, 706-711, (1991);
Lindsey and Wagner, J. Org. Chem. 54, 828-836, (1989); and
Zipplies, et al., J. Am. Chem. Soc. 108, 4433-4445, (1986). See,
also, Meltze; Phthalocyanine Technology in Chemical Process Reviews
No. 42.; Noyes Data Corp. Park Ridge, N.J. (1970). See, also,
Goedken, et al., J.C.S. Chem. Comm. 337-338, (1973); Martin, and
Cummings, Inorg. Chem. 12, 1477-1482, (1973); Riley, et al., J. Am.
Chem. Soc. 98, 1752-1762, (1976); Dabrowiak, et al., J. Am. Chem.
Soc. 95, 6613-6622, (1973); Riley and Busch, Inorg. Chem. 23,
3235-3241, (1984); Watkuns, et al., Inorg. Chem. 15, 387-393,
(1976); and Riley, et al., J. Am. Chem. Soc. 99, 767-777, (1977).
Pyridinium porphyrins can also be synthesized as described in Hunt
et al., in Chem. & Biol. 4:845-58, 1997. Substituted porphyrins
can also be synthesized as described herein.
[0102] Where a substituent is designated as, or can be, a hydrogen,
the exact chemical nature of a substituent which is other than
hydrogen at that position, e.g., a hydrocarbonyl radical or a
halogen, hydroxy, amino and the like functional group, is not
critical so long as it does not adversely affect the overall
activity and/or synthesis procedure. Where a ligand (L.sub.1 and
L.sub.2) or a charge neutralizing anion is designated as a
particular chemical entity, the exact chemical nature of a ligand
or a charge neutralizing anion which is other than the particular
chemical entity depicted is not critical so long as it does not
adversely affect the overall activity and/or synthesis
procedure.
[0103] Properties of the 2-pyridyl compounds of the invention can
be determined using methods known in the art. For example, methods
for determining pKa, electronic absorption spectra, phosphate
binding, cyanide binding, EPR spectroscopy in the presence of
increasing KCN concentrations, magnetic susceptibility, ascorbate
reduction, and electrochemical reduction are described in methods
for electronic spectral, magnetic and electrochemical properties of
imidazolyl-containing compounds as described in D. E. Lahaye,
Water-Soluble meso Imidazolyl Manganese Porphyrins Biomimetics and
Oxidation Catalysis, Doctoral Dissertation, Princeton University,
2005.
Synthesis of Amphiphilic Catalysts and Preparation of Vesicular
Assembly Systems According to the Invention
[0104] The invention includes amphiphilic compounds. In one
embodiment, the amphiphic compound contains a metallic complex,
e.g., a metallic porphyrin compound. Porphyrin compounds can be
synthesized as described generally in Hunt et al., in Chem. &
Biol. 4:845-58, 1997. Substituted metallic complex amphiphiles
within the invention are prepared by methods known in the art.
Polyether cascade dendritic porphyrins can be prepared resulting in
a symmetrical solution dendrimer. If desired, unsymmetrical
derivatives with a single hydrophobic side chain can be readily
prepared by procedures known in the art. While not wishing to be
bound by theory, it is believed the side chains of the invention
(R.sub.1, R.sub.2, R.sub.3, and R.sub.4 when present) lower
toxicity by minimizing or preventing liver uptake, thereby allowing
the compound to be maintained longer in a subject's blood pool. If
desired, targeting agents such as steroids can be attached.
[0105] Amphiphilic porphyrin compound analogs can include end
products synthesized using procedures generally described Hunt et
al., in Chem. & Biol 4:845-58, 1997. For example, iron and
manganese porphyrins can be constructed by using as starting
materials pyridinium porphyrins that are synthesized according to
methods known to those skilled in the art and referenced above. For
example, pyridinium porphyrins can be synthesized by peralkylation
of 5, 10, 15, 20,-tetrakis(4-pyridyl)porphine with an appropriate
alkyl iodide, e.g., dodecyl iodide.
[0106] Porphyrins preferably are located in a hydrophilic
environment for the efficient catalysis of peroxynitrite. Thus, in
preferred embodiments, the invention includes PEG-linked
(polyethylene glycol) substituted porphyrin compounds. In certain
aspects of the invention, these porphyrins can be provided in
vesicular assemblies, such as liposomes. In such an environment,
the PEG-linkers extend the metalloporphyrin head group away from
the interfacial region between the membrane and external solution
and further into the bulk solvent. The hydrophilicity of the
porphyrin head group correlates with the efficiency of the
catalysts: the rate of peroxynitrite decomposition is much faster
when catalyzed by PEG-linked metalloporphyrins, as compared to
metalloporphyrins with simple dodecyl chains. In some embodiments,
tocopherol, e.g., a tocopherol or, preferably, y tocopherol, is
also present in the vesicular assembly.
[0107] The compounds can possess one or more asymmetric carbon
atoms and are thus capable of existing in the form of optical
isomers as well as in the form of racemic or nonracemic mixtures
thereof. The optical isomers can be obtained by resolution of the
racemic mixtures according to conventional processes, including by
formation of diastereoisomeric salts through treatment with an
optically active acid (e.g., tartaric, diacetyltartaric,
dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic) and then
separation of the mixture of diastereoisomers by crystallization
followed by liberation of the optically active bases from these
salts. Another process for separation of optical isomers involves
the use of a chiral chromatography column optimally chosen to
maximize the separation of the enantiomers. Still another available
method involves synthesis of covalent diastereoisomeric molecules
by reacting one or more secondary amine group(s) of the compounds
of the invention with an optically pure acid in an activated form
or an optically pure isocyanate. The synthesized diastereoisomers
can be separated by conventional means such as chromatography,
distillation, crystallization or sublimation, and then hydrolyzed
to deliver the enantiomerically pure ligand. The optically active
compounds of the invention can likewise be obtained by utilizing
optically active starting materials, such as natural amino
acids.
[0108] The chemical reactions shown by the references described
above are generally disclosed in terms of variations appropriate
for their broadest application to the preparation of the compounds
of this invention. Occasionally, the reactions may not be
applicable as described to each compound included within the
disclosed scope. The compounds for which this occurs will be
readily recognized by those skilled in the art. In all such cases,
either the reactions can be successfully performed by conventional
modifications known to those skilled in the art, e.g., by
appropriate protection of interfering groups, by changing to
alternative conventional reagents, by routine modification of
reaction conditions, or the like. Alternatively, other reactions
disclosed herein or otherwise conventionally known, will be
applicable to the preparation of the corresponding compounds of
this invention. In all preparative methods, all starting materials
are known or can be readily prepared from known starting
materials.
[0109] Additional methods for synthesizing compounds according to
the invention are described in the Examples, below.
Screening Compounds for Catalytic Activity
[0110] To screen compounds for peroxynitrite decomposition
catalytic activity of the invention, peroxynitrite is prepared and
isolated as its sodium salt by the reaction of acidic hydrogen
peroxide with sodium nitrite followed by rapid quenching with NaOH
as set out by Halfpenny and Robinson, in J. Chem. Soc., 928-938
(1952). Peroxynitrite has an absorbance maximum at 302 nm with an
extinction coefficient of 1670 M.sup.-1 cm.sup.-1. Therefore, it is
possible to directly observe the decomposition of peroxynitrite by
monitoring the change in absorbance at 302 nm by stop-flow
spectrophotometric analysis. For example, the decomposition of
peroxynitrite at an accelerated rate (relative to the natural
decomposition rate of peroxynitrite) upon the addition of the
decomposition catalysts of the invention.
[0111] In addition, it is known that peroxynitrite inactivates
CuZn-SOD (superoxide dismutase) enzyme in a concentration dependant
manner. Peroxynitrite is also reported to inactivate Mn-SOD. See
Ischiropoulos et al., Archives of Biochemistry and Biophysics,
298:2, 431-437 (1992). The invention provides compounds and methods
for screening for compounds which protect CuZn-SOD or Mn-SOD by
inactivating peroxynitrite.
[0112] Peroxynitrite catalytic activity can also be measured using
methods described in Hunt et al., Chem. & Biol. 4:845-58,
1997.
Pharmaceutical Compositions
[0113] The pharmaceutical compositions of the invention include a
pharmaceutically effective amount of one or more of the compounds
of the invention administered in a dosage regimen appropriate for
treating a disease condition. The dosage regimen is selected in
accordance with a variety, of factors, including the type, age,
weight, sex, diet and medical condition of the patient, the
severity of the disease, the route of administration,
pharmacological considerations such as the activity, efficacy,
pharmacokinetic and toxicology profiles of the particular compound
employed, whether a drug delivery system is utilized and whether
the compound is administered as part of a drug combination. Thus,
the dosage regimen actually employed may vary widely and therefore
may deviate from the preferred dosage regimen set forth above.
[0114] For example, total daily dose administered to a mammal in
single or divided doses may be in amounts, for example, from about
1 to about 100 mg/kg body weight daily and more usually about 3 to
30 mg/kg. Dosage unit compositions may contain such amounts of
submultiples thereof to make up the daily dose. The number of
submultiples is preferably about one to three times per day of
about 30 mg/kg per unit dosage form. The serum concentrations of
the doses are about 1 pM to 1.5 .mu.M, e.g., 3 pM-1.0 .mu.M, 300 pM
to 750 nM, 500 pM to 250 nM, or 1 nm to 125 nM. Furthermore, the
amount of active ingredient that may be combined with the carrier
materials to produce a single dosage form will vary depending upon
the host treated and the particular mode of administration.
[0115] The invention also includes pharmaceutical compositions
suitable for decomposing peroxynitrite in a cell both in vivo and
in vitro. More preferably, the invention includes pharmaceutical
compositions suitable for decomposing peroxynitrite under
physiological conditions. The compositions are preferably suitable
for internal use and include an effective amount of a
pharmacologically active compound of the invention, alone or in
combination, with one or more pharmaceutically acceptable carriers.
The compounds are especially useful in that they have very low, if
any toxicity.
[0116] In practice, the compounds of the inventions or their
pharmaceutically acceptable salts, are administered in amounts
which will be sufficient to inhibit inflammatory conditions or
disease and/or prevent the development of inflammation or
inflammatory disease in animals or mammals, and are used in the
pharmaceutical form most suitable for such purposes.
[0117] Preferred pharmaceutical compositions are tablets and
gelatin capsules comprising the active ingredient together with a)
diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol,
cellulose and/or glycine; b) lubricants, e.g., silica, talcum,
stearic acid, its magnesium or calcium salt and/or
polyethyleneglycol; for tablets also c) binders, e.g., magnesium
aluminum silicate, starch paste, gelatin, tragacanth,
methylcellulose, sodium carboxymethylcellulose and/or
polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches,
agar, alginic acid or its sodium salt, or effervescent mixtures;
and/or e) absorbents, colorants, flavors and sweeteners. Injectable
compositions are preferably aqueous isotonic solutions or
suspensions, and suppositories are advantageously prepared from
fatty emulsions or suspensions. The compositions may be sterilized
and/or contain adjuvants, such as preserving, stabilizing, wetting
or emulsifying agents, solution promoters, salts for regulating the
osmotic pressure and/or buffers. In addition, they may also contain
other therapeutically valuable substances. The compositions are
prepared according to conventional mixing, granulating or coating
methods, respectively, and contain about 0.1 to 75%, preferably
about 1 to 50%, of the active ingredient. Administration of the
active metallic complexes of the inventions and salts described
herein can be via any of the accepted modes of administration for
therapeutic agents. These methods include systemic or local
administration such as oral, nasal, parenteral, transdermal,
subcutaneous, or topical administration modes.
[0118] Depending on the intended mode of administration, the
compositions may be in solid, semi-solid or liquid dosage form,
such as, for example, injectables, tablets, suppositories, pills,
time-release capsules, powders, liquids, suspensions, or the like,
preferably in unit dosages. The compositions will include an
effective amount of active compound of the invention or the
pharmaceutically acceptable salt thereof, and in addition, and may
also include any conventional pharmaceutical excipients and other
medicinal or pharmaceutical drugs or agents, carriers, adjuvants,
diluents, etc., as are customarily used in the pharmaceutical
sciences.
[0119] For solid compositions, excipients include pharmaceutical
grades of mannitol, lactose, starch, magnesium stearate, sodium
saccharin, talcum, cellulose, glucose, sucrose, magnesium
carbonate, and the like may be used. The compounds of the invention
may be also formulated as suppositories using for example,
polyalkylene glycols, for example, propylene glycol, as the
carrier.
[0120] Liquid, particularly injectable compositions can, for
example, be prepared by dissolving, dispersing, etc. The compound
of the invention is dissolved in or mixed with a pharmaceutically
pure solvent such as, for example, water, saline, aqueous dextrose,
glycerol, ethanol, and the like, to thereby form the injectable
solution or suspension.
[0121] If desired, the pharmaceutical composition to be
administered may also contain minor amounts of non-toxic auxiliary
substances such as wetting or emulsifying agents, pH buffering
agents, and other substances such as for example, sodium acetate,
triethanolamine oleate, etc.
[0122] Parental injectable administration is generally used for
subcutaneous, intramuscular or intravenous injections and
infusions. Injectables can be prepared in conventional forms,
either as liquid solutions or suspensions or solid forms suitable
for dissolving in liquid prior to injection. One approach for
parenteral administration employs the implantation of a
slow-release or sustained-released systems, which assures that a
constant level of dosage is maintained, according to U.S. Pat. No.
3,710,795.
[0123] The compounds of the invention can be administered in such
oral dosage forms as tablets, capsules (each including timed
release and sustained release formulations), pills, powders,
granules, elixers, tinctures, suspensions, syrups and emulsions.
Likewise, they may also be administered in intravenous (both bolus
and infusion), intraperitoneal, subcutaneous or intramuscular form,
all using forms well known to those of ordinary skill in the
pharmaceutical arts.
[0124] The dosage regimen utilizing the compounds is selected in
accordance with a variety of factors including type, species, age,
weight, sex and medical condition of the patient; the severity of
the condition to be treated; the route of administration; the renal
and hepatic function of the patient; and the particular compound or
salt thereof employed. An ordinarily skilled physician or
veterinarian can readily determine and prescribe the effective
amount of the drug required to prevent, counter or arrest the
progress of the condition.
[0125] Oral dosages of the invention, when used for the indicated
effects, will range between about 0.05 to 1000 mg/day orally. The
compositions are preferably provided in the form of scored tablets
containing 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100.0,
250.0, 500.0 and 1000.0 mg of active ingredient. Effective plasma
levels of the compounds of the invention range from 0.002 mg to 50
mg per kg of body weight per day.
[0126] Compounds of the invention may be administered in a single
daily dose, or the total daily dosage may be administered in
divided doses of two, three or four times daily. Furthermore,
compounds for the invention can be administered in intranasal form
via topical use of suitable intranasal vehicles, or via transdermal
routes, using those forms of transdermal skin patches well known to
those of ordinary skill in that art. To be administered in the form
of a transdermal delivery system, the dosage administration will,
of course, be continuous rather than intermittent throughout the
dosage regimen. Other preferred topical preparations include
creams, ointments, lotions, aerosol sprays and gels, wherein the
concentration of active ingredient would range from 0.1% to 15%,
w/w or w/v.
[0127] The compounds herein described in detail can form the active
ingredient, and are typically administered in admixture with
suitable pharmaceutical diluents, excipients or carriers
(collectively referred to herein as "carrier" materials) suitably
selected with respect to the intended form of administration, that
is, oral tablets, capsules, elixirs, syrups and the like, and
consistent with conventional pharmaceutical practices.
[0128] For instance, for oral administration in the form of a
tablet or capsule, the active drug component can be combined with
an oral, non-toxic pharmaceutically acceptable inert carrier such
as ethanol, glycerol, water and the like. Moreover, when desired or
necessary, suitable binders, lubricants, disintegrating agents and
coloring agents can also be incorporated into the mixture. Suitable
binders include starch, gelatin, natural sugars such as glucose or
beta-lactose, corn sweeteners, natural and synthetic gums such as
acacia, tragacanth or sodium alginate, carboxymethylcellulose,
polyethylene glycol, waxes and the like. Lubricants used in these
dosage forms include sodium oleate, sodium stearate, magnesium
stearate, sodium benzoate, sodium acetate, sodium chloride and the
like. Disintegrators include, without limitation, starch, methyl
cellulose, agar, bentonite, xanthan gum and the like.
[0129] The compounds of the invention can also be administered in
the form of liposome delivery systems, such as small unilamellar
vesicles, large unilamellar vesicles and multilamellar vesicles.
Liposomes can be formed from a variety of phospholipids, containing
cholesterol, stearylamine or phosphatidylcholines. In some
embodiments, a film of lipid components is hydrated with an aqueous
solution of drug to a form lipid layer encapsulating the drug, as
described in U.S. Pat. No. 5,262,564.
[0130] Compounds of the invention may also be delivered by the use
of monoclonal antibodies as individual carriers to which the
metallic complex molecules are coupled. The compounds of the
invention may also be coupled with soluble polymers as targetable
drug carriers. Such polymers can include polyvinylpyrrolidone,
pyran copolymer, polyhydroxypropyl-methacrylamide-phenol,
polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine
substituted with palmitoyl residues. Furthermore, the metallic
complexes of the invention may be coupled to a class of
biodegradable polymers useful in achieving controlled release of a
drug, for example, polylactic acid, polyepsilon caprolactone,
polyhydroxy butyric acid, polyorthoesters, polyacetals,
polydihydropyrans, polycyanoacrylates and cross-linked or
amphipathic block copolymers of hydrogels. Any of the above
pharmaceutical compositions may contain 0.1-99%, preferably 1-70%
of the active compound.
[0131] While the compounds of the invention can be administered as
the sole active pharmaceutical agent, they can also be used in
combination with one or more compounds of the invention or with one
or more compounds which are known to be effective against the
specific disease state that one is targeting for treatment.
Therapeutic Methods
[0132] The invention also provides methods for preventing or
reducing cellular damage resulting from exposure to various
chemical compounds which produce potentially damaging free radical
species, comprising administering a therapeutically or
prophylactically efficacious dosage of at least one species of a
substituted compound of the invention, e.g., a substituted
metalloporphyrin.
[0133] Compositions including the herein described compounds may be
administered for various indications, including: (1) for preventing
ischemic reoxygenation injury in a patient, (2) for preserving
organs for transplant in an anoxic, hypoxic, or hyperoxic state
prior to transplant, (3) for protecting normal tissues from free
radical-induced damage consequent to exposure to ionizing radiation
and/or chemotherapy, as with bleomycin, (4) for protecting cells
and tissues from free radical-induced injury consequent to exposure
to xenobiotic compounds which form free radicals, either directly
or as a consequence of monooxygenation through the cytochrome P-450
system, (5) for enhancing cryopreservation of cells, tissues,
organs, and organisms by increasing viability of recovered
specimens, and (6) for prophylactic administration to prevent:
carcinogenesis, cellular senescence, cataract formation, formation
of malondialdehyde adducts, HJV pathology and macromolecular
crosslinking, such as collagen crosslinking. In one aspect of the
invention, compounds of the invention are formulated for
administration by the oral route by forming a pharmaceutical dosage
form comprising an excipient and not less than 1 microgram nor more
than about 10 grams of at least one antioxidant complex of the
invention. Dietary formulations are administered for therapy of
free radical-induced diseases and/or for the chemoprevention of
neoplasia and/or oxidative damage associated with normal aerobic
metabolism.
[0134] In another aspect, buffered aqueous solutions comprising one
or more antioxidant substituted compounds of the invention at a
concentration of at least 1 nM but not more than about 100 mM is
formulated for administration, usually at a concentration of about
0.1 to 10 mM, to a patient undergoing or expected to undergo: (1)
an ischemic episode, such as a myocardial infarction, cerebral
ischemic event, transplantation operation, open heart surgery,
elective angioplasty, coronary artery bypass surgery, brain
surgery, renal infarction, traumatic hemorrhage, tourniquet
application, (2) antineoplastic or antihelminthic chemotherapy
employing a chemotherapeutic agent which generates free radicals,
(3) endotoxic shock or sepsis, (4) exposure to ionizing radiation,
(5) exposure to exogenous chemical compounds which are free
radicals or produce free radicals, (6) thermal or chemical burns or
ulcerations, (7) hyperbaric oxygen, or (8) apoptosis of a
predetermined cell population (e.g., lymphocyte apoptosis).
Administration can be via any desired route, e.g., intravenous,
subcutaneous, inhalation, intramuscular. The buffered aqueous
solutions may also be used, typically in conjunction with other
established methods, for organ culture, cell culture, transplant
organ maintenance, and myocardial irrigation. Non-aqueous
formulations, such as lipid-based formulations are also provided,
including stabilized emulsions. The invention also encompasses
pharmaceutical compositions of compounds of the invention,
therapeutic uses of such compounds, methods and compositions for
using these compounds in diagnostic, therapeutic, and research
applications in human and veterinary medicine.
[0135] Another aspect of the invention is its use in enhancing the
recovery of skin of a warm-blooded animal from wounds, such as
surgical incisions, burns, inflammation or minor irritation due to
oxidative damage, etc. This method includes administering to the
skin wound or irritation a therapeutically or, in some cases a
prophylactically effective amount of a composition which comprises
a compound of the invention as described herein. Additionally, the
invention provides a method of treating a peroxide-induced
condition in a subject which comprises administering to the subject
an amount of any of the compounds of the invention effective to
reduce peroxide in a subject and thereby treat the peroxide-induced
condition. Administration of the compound to the subject may be
effected by means other than those listed herein. Further, the
peroxide-induced condition may involve cataracts, inflammation of a
tissue, ischemia, an allergic reaction, or pathology caused by
oxidative stress. Where the peroxide-induced condition involves
cataracts, administration is effected by, but is not limited to,
topical contact to the surface of an eye.
[0136] The method includes contacting the cell with any compound of
formula I in a pharmaceutically effective amount, that is,
sufficient to actively decompose peroxynitrite in the cell. In
general, any cell having peroxynitrite, or capable of synthesizing
peroxynitrite, can be treated. The cell can be provided in any form
so long as it is accessible to the compound. For example, the cell
can be provided in vitro, ex vivo, or in vivo. Peroxynitrite
decomposition can be measured using any method known in the art,
e.g., methods such as stopped-flow kinetic analysis.
[0137] Also provided in the invention is a method of inhibiting,
preventing, or treating a pathology advantageous affected by the
decomposition of peroxynitrite in a mammal. The disease or
pathology can be associated, e.g., with an inflammatory disease or
neurodegenerative disease characterized by the presence of
peroxynitrite. Inflammatory diseases refer to diseases or
conditions where there is an inflammation of the body tissue.
Neurodegenerative diseases refer to diseases causing the breakdown
of neural tissue and/or function. These both include local
inflammatory responses and systemic inflammation. Examples of such
diseases and conditions include: complications of organ
transplantation including lung transplantation, including
bronchitis, including obliterative bronchitis; chronic inflammatory
disorders of the joints, including arthritis, rheumatoid arthritis,
osteoarthritis and bone diseases associated with increased bone
resorption; inflammatory bowel diseases such as ileitis, colitis,
including ulcerative colitis, Barrett's syndrome, and Crohn's
disease; inflammatory lung disorders such as asthma, adult
respiratory distress syndrome, and chronic obstructive airway
disease; inflammatory disorders of the eye including corneal
dystrophy, trachoma, onchocerciasis, uveitis, sympathetic
ophthalmitis and endophthalmitis; chronic inflammatory disorders of
the gum, including gingivitis and periodontitis; tuberculosis;
leprosy; inflammatory diseases of the kidney including uremic
complications, glomerulonephritis and nephrosis; inflammatory
disorders of the skin including sclerodermatitis, psoriasis and
eczema; inflammatory diseases of the central nervous system,
including chronic demyelinating diseases of the nervous system,
multiple sclerosis, AIDS-related neurodegeneration, Alzheimer's
disease, infectious meningitis, encephalomyelitis, Parkinson's
disease, Huntington's disease, amyotrophic lateral sclerosis and
viral or autoimmune encephalitis; autoimmune diseases such as
diabetes, including diabetic neuropathy, vascular complications of
diabetes, and diabetes mellitus, immune-complex vasculitis,
systemic lupus erythematosus (SLE); inflammatory diseases of the
heart such as cardiomyopathy, ischemic heart disease,
hypercholesterolemia, atherosclerosis, doxorubucin-induced cardiac
dysfunction; as well as various other diseases with significant
inflammatory components, including preeclampsia; chronic liver
failure, brain and spinal cord trauma, and cancer. There may also
be a systemic inflammation of the body, exemplified by
gram-positive or gram negative shock, hemorrhagic or anaphylactic
shock, or shock induced by cancer chemotherapy in response to
pro-inflammatory cytokines.
[0138] The invention also includes a method of treating,
preventing, or otherwise inhibiting reperfusion injury in a subject
in need of treatment, prevention, or inhibition thereof. The method
includes administering a peroxynitrite decomposition catalyst i.e.,
a compound of the invention as disclosed herein in an amount
sufficient to inhibit reperfusion injury in the subject.
Reperfusion refers to the process whereby blood flow in the blood
vessels is resumed after blood flow has been interrupted, such as
occurs following constriction or obstruction of the vessel.
Reperfusion is typically associated with ischemia and may result
following a naturally occurring episode, such as a myocardial
infarction or stroke, or during a surgical procedure where blood
flow in vessels is purposely or unintentionally blocked off.
[0139] The subject in the above-mentioned methods can be, e.g., a
mammal, e.g., a human, mouse, rat, dog, cat, horse, cow, pig, or
non-human primate. Administration can be systemic or topical, and
can be prophylactic or therapeutic.
EXAMPLES
[0140] The invention will be further described in the following
examples, which do not limit the scope of the invention described
in the claims.
Example 1
Synthesis of zinc(II)-2-TRMBzPyP
Synthesis of R-(+)-methylbenzybromoacetamide
[0141] (Liu, S.; Pietryka, J.; Ellars, C. E.; Edwards, D. S.
Bioconjugate Chem. 2002, 13, 902-913).
[0142] To 20 mL of dry dioxane was added 0.48 g (3.47 mmol)
bromoacetic acid and 0.39 g (3.47 mmol) N-hydroxysuccinimide. DCC,
0.79 g (3.82 mmol) was dissolved in 10 mL dioxane and added via
pipette to the stirred solution. Dicyclohexylurea precipitated as a
milky solid and was filtered off after 2 hr.
(R)-(+)-methylbenzylamine, 0.37 g (3.13 mmol) was added to the
filtrate and the mixture was stirred for 5 hr, until the reaction
was complete by tic. The dioxane was removed and the residue was
taken up in EtOAc, and the organic layer was washed with 40 mL 10%
citric acid, 40 mL NaCO.sub.3, and brine. The organic layer was
dried over Na.sub.2SO.sub.4 and the solvent was removed to leave
(R)-(+)-methylbenzylbromoacetamide (5) as a white solid.
Purification by column chromatography (2:8 EtOAc:CH.sub.2Cl.sub.2)
left the bromoacetamide in 80% yield as a fluffy white solid.
EI-MS: parent ion peak at 242 (Calculated mass 242). .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta.1.55 (d, 3H, J=7.0 Hz, CHCH.sub.3)
.delta.3.89 (dd, 2H, J=17.0 Hz, BrCH.sub.2CO) 65.10 (quintet, 1H,
J=7.0 Hz, CHCH.sub.3) .delta.6.8 (br s, 1H, NH) 67.3 (m, 5H,
phenyl)
Synthesis of 2-tetrakis-(N--R-(+)-methylbenzylacetamido)-pyridyl
porphyrin
[0143] To 3 mL of anhydrous DMF under N.sub.2 was added 25 mg (0.04
mmol) 2-PyP and 1 g (4.12 mmol) (R)-(+)-methylbenzylbromoacetamide.
The reaction was allowed to stir at 100-110.degree. C. for 6 hr,
until .lamda..sub.max had shifted from .lamda.=418 nm to
.lamda.=422 nm and an aliquot of reaction mixture partitioned
between CHCl.sub.3 and H.sub.2O showed no color in the water layer.
The reaction mixture was cooled and dropped into rapidly stirred
ether, then filtered. The precipitated porphyrin was dissolved in
10 mL H.sub.2O and extracted with 2.times.20 mL CHCl.sub.3, then
precipitated by the addition of a concentrated solution of
NH.sub.4PF.sub.6 in H.sub.2O. The hexafluorophosphate salt of the
porphyrin was filtered off and washed with H.sub.2O. This salt was
then dissolved in acetone and applied to a 3.times.12 cm column of
normal phase silica gel packed in 8:1:1 CH.sub.3CN:H.sub.2O:sat.
aq. KNO.sub.3. Fractions with R.sub.f=0.63 were collected. The
appropriate fractions were concentrated until the porphyrin just
began to precipitate, then just enough CH.sub.3CN was added to the
solution to re-dissolve the porphyrin. A saturated solution of
NH.sub.4PF.sub.6 in H.sub.2O was then added, and the porphyrin
precipitated as a fine powder, which could be filtered onto Celite
and washed. The hexafluorophosphate salt of 2-TMBzPyP was isolated
as a red-purple solid in 32% yield. High-Resolution ESI-MS:
{2-TRMBzPyP-H.sup.+}.sup.3+ (m/z=421.8642 Calculated=421.8625)
Synthesis of zinc(II)-2-TRMBzPyP
[0144] .alpha..alpha..beta..beta.-2-TRMBzPyP, 15 mg
(9.5.times.10.sup.-3 mmol) and zinc(II)acetate, 20.7 mg (0.095
mmol) were dissolved in a mixture of water and methanol and stirred
at room temperature overnight. The formation of the zinc porphyrin
was confirmed by a shift in the porphyrin soret from 422 to 434 nm
in methanol. The solvent was evaporated and the porphyrin was
purified by double precipitation as described in the synthesis of
the Mn(III)porphyrin.
[0145] ESI-MS data: 455 {Zn-2-TRMBzPyP-Cl}.sup.3+(calculated m/z
455.2) and 701 {Zn-2-TRMBzPyP-2Cl}.sup.2+(calculated m/z 700.6).
UV-visible (water, pH 9.09 borate buffer): .lamda..sub.max
(log.sub.10.epsilon.) 431 (5.27) 560 (4.12) 594 (3.64)
Example 2
Synthesis of zinc(II)-2-TRBor PyP
Synthesis of R-(+)-bornylbromoacetamide
[0146] Bromoacetic acid, 503 mg (3.62 mmol), N-hydroxysuccinimide,
417 mg (3.62 mmol) and DCC, 823 mg (3.98 mmol) were dissolved in 50
mL dioxane in an oven dried flask and stirred for an hr. After an
hr the reaction mixture was filtered and 500 mg (3.26 mmol)
R-(+)-bornylamine was added to it. The reaction mixture was stirred
overnight and the reaction was stopped when there was no unreacted
starting material as checked by TLC. The solvent was evaporated and
the residue was redissolved in ethyl acetate and washed with 10%
citric acid, 5% sodium carbonate and saturated NaCl solutions. The
organic layer was dried over sodium sulfate and evaporated to give
the crude product which was purified by silica gel column
chromatography (1:9 EtOAc:CH.sub.2Cl.sub.2) to yield 847 mg (94%)
R-(+)-bornylbromoacetamide.
Synthesis of 2-tetrakis-(N--R-(+)-bornylacetamido)-pyridyl
porphyrin
[0147] 2-PyP, 25 mg (0.04 mmol) and R-(+)-bornylbromoacetamide, 517
mg (1.88 mmol) were dissolved in 5 mL dry DMF in an oven dried and
flame dried flask. The reaction mixture was heated to 100.degree.
C. and stirred for 27 hr under argon atmosphere. The reaction was
monitored by UV-Visible spectroscopy by removing aliquots of the
reaction mixture and dissolving in methanol. The porphyrin soret
band shifted from 412 nm to 420 nm during the course of the
reaction. The reaction mixture was cooled to room temperature and
added dropwise to 50 mL anhydrous ethyl ether. The crude product
precipitated and was collected by filtration over celite and
dissolved in methanol. The solvent was evaporated and the residue
redissolved in minimum volume of water. The product was
reprecipitated with ammonium hexafluorophosphate and collected by
filtration over celite. The product was dissolved in acetone and
the solvent was stripped. Residual water was evaporated by
azeotroping with methanol. The residue was dissolved in minimum
volume of acetone and reprecipitated with tetra-butyl ammonium
chloride. The product was collected by filtration over celite,
washed with acetone to remove excess tetra-butyl ammonium chloride
and dissolved in methanol. The solvent was stripped to give the
crude product which was purified by semi-preparative HPLC to give
pure 25 mg (47%)
.alpha..alpha..beta..beta.-tetra-(R-bornylacetamido)-2-pyridylporphyrin.
High-Resolution ESI-MS: {2-TRBorPyP-H.sup.+}.sup.3+(m/z=464.6136
Calculated=464.6126)
Synthesis of zinc(II)-2-TRBor PyP
[0148] .alpha..alpha..beta..beta.-2-TRBor PyP, 10 mg
(5.83.times.10.sup.-3 mmol) and zinc(II)acetate, 13 mg (0.0583
mmol) were dissolved in a mixture of water and methanol and stirred
at room temperature overnight. The formation of the zinc porphyrin
was confirmed by a shift in the porphyrin soret from 422 to 436 nm
in methanol. The solvent was evaporated and the porphyrin was
purified by double precipitation as described in the synthesis of
the Mn(III)porphyrin. ESI-MS data: 498 {Zn-2-TRBor
PyP-Cl}.sup.3+(calculated m/z 498.2) and 764 {Zn-2-TRBor
PyP-2Cl}.sup.2+(calculated m/z 764.6). UV-visible (water, pH 9.54
borate buffer): .lamda..sub.max (log.sub.10.epsilon.) 430 (4.93)
560 (3.85) 595 (3.44)
Example 3
Synthesis of Iron(III) chloride
meso-tetrakis-2-(N-(2-methoxy)ethyl)pyridyl porphyrin
Synthesis of 2-methoxyethyl tosylate
[0149] 2-methoxyethanol (0.989 g, 13 mmol) was dissolved in 30 ml
dichloromethane, and triethylamine (2.53 g, 25 mmol) was added to
the solution. The reaction mixture was set to stir in an ice-water
bath, and p-toluenesulfonyl chloride (3.22 g, 17 mmol) was added
all at once. The ice was allowed to melt, and the reaction was
continued overnight. The reaction mixture was then filtered, to
remove all of the triethylamine hydrochloride, and the filtrate was
washed with 30 ml saturated NaHCO.sub.3(aq), then 30 ml 1N
KHSO.sub.4(aq), then 30 ml saturated NaHCO.sub.3(aq). The organic
layer was dried over anhydrous magnesium sulfate, and the solvent
was removed by distillation. The colorless oily residue was
chromatographed on silica gel in 1:5 ethyl acetate:chloroform, to
yield 2.77 g (92% yield) of 2-methoxyethyl tosylate as a viscous
liquid.
[0150] .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.2.4 (s, 3H,
ArCH.sub.3), .delta.3.3 (s, 3H, --OCH.sub.3), .delta.3.6 (m, 2H,
--CH.sub.2OCH.sub.3), .delta.4.1 (m, 2H, --CH.sub.2OSO.sub.2Ar),
.delta.7.3 (d, J=8.5 Hz, 2H, --SO.sub.2CHCHCCH.sub.3), .delta.7.8
(d, J=8.5 Hz, 2H, --SO.sub.2CHCHCCH.sub.3).
Synthesis of meso-tetrakis-2-(N-(2-methoxy)ethyl)pyridyl
porphyrin
[0151] In an oven-dried flask under argon, were combined
meso-tetrakis-2-pyridyl porphyrin (2-PyP; 0.091 g, 0.148 mmol) and
2-methoxyethyl tosylate (1.33 g, 5.77 mmol) in 1.37 ml anhydrous
DMF. The reaction mixture was heated to 100.degree. C. and stirred
for 18 h 30 min. Reaction progress was monitored by reverse-phase
HPLC. Once complete, the reaction mixture was cooled to room
temperature before being added dropwise to diethyl ether, to
precipitate out the product and remove DMF and excess alkylating
agent. The porphyrin was filtered onto Celite and washed off with
water. The porphyrin was precipitated from water as the
hexafluorophosphate salt with saturated NH.sub.4PF.sub.6(aq) added
dropwise. The porphyrin was again filtered onto Celite, and washed
off with acetone. Saturated tetrabutylammonium chloride (in
acetone) was added dropwise to precipitate out the porphyrin as the
chloride salt. The gummy precipitate was again filtered onto Celite
and washed well with dry acetone, to thoroughly remove any
lingering salts, and finally washed off with methanol. The
porphyrin was then chromatographed on Sephadex LH-20 in 1:1
methanol:water as the eluant, and collection of appropriate
fractions yielded meso-tetrakis-2-(N-(2-methoxy)ethyl)pyridyl
porphyrin in 65% yield. .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta.2.8-3.0 (singlets, 12H, --CH.sub.2OCH.sub.3), .delta.3.2-3.4
(m, 8H, --CH.sub.2OCH.sub.3), .delta.4.8 (m, 8H, N.sup.+CH.sub.2),
.delta.8.6 (m, 4H, N.sup.+CHCH), .delta.8.8-9.1 (m, 8H,
N.sup.+CHCHCH and N.sup.+CCH), .delta.8.8-9.4 (br s, 8H, pyrrole),
.delta.9.5 (m, 4H, N.sup.+CH). Partial UV-Vis (H.sub.2O) (log
.epsilon.): 417 (5.31).
Synthesis of Iron(III) chloride
meso-tetrakis-2-(N-(2-methoxy)ethyl)pyridyl porphyrin
[0152] Free base meso-tetrakis-2-(N-(2-methoxy)ethyl)pyridyl
porphyrin (0.055 g, 0.055 mmol) was dissolved in 10 ml deionized
water, ferrous ammonium sulfate hexahydrate (0.018 g, 0.295 mmol)
was added, and the reaction mixture was refluxed until the
porphyrin Soret shifted to 412 nm and the number of Q bands had
reduced from 4 to 2 (approximately 10 h). The reaction mixture was
cooled to room temperature, and BioRad AG1X8 chloride ion exchange
resin (0.501 g) was added and allowed to stir for 2 h. The resin
was filtered off, the filtrate was neutralized, and the solvent was
removed by distillation. The residue was chromatographed on
Sephadex LH-20 in 1:1 methanol:water as the eluant. Collection of
appropriate fractions yielded iron(III) chloride
meso-tetrakis-2-(N-(2-methoxy)ethyl)pyridyl porphyrin in 99%
yield.
[0153] Partial UV-Vis (H.sub.2O) (log .epsilon.): 412 (4.76).
Example 4
Synthesis of Iron(III) chloride
meso-tetrakis-2-(N-2-methoxyethylacetamido)pyridyl porphyrin
Synthesis of 2-methoxyethylbromoacetamide
[0154] 2-methoxyethylamine (0.750 g, 10 mmol) was dissolved in 50
ml dichloromethane in a 100-ml round-bottom flask, and cooled in an
ice-water bath. Bromoacetyl bromide (1 g, 5 mmol) was added
dropwise via syringe, and the reaction was continued overnight. The
reaction mixture was added to 260 ml ethyl acetate and 2.5 ml
dichloromethane, and the solution was washed with two portions each
of water and of saturated NaCl.sub.(aq). The organic layer was
dried over anhydrous magnesium sulfate, and the solvent was removed
by distillation to leave 0.64 g of 2-methoxyethylbromoacetamide
(66% yield) as a yellow oil.
[0155] 1H NMR (300 MHz, CDCl.sub.3): .delta.3.36 (s, 3H,
OCH.sub.3), .delta.3.46 (m, 4H, CH.sub.2H.sub.2OCH.sub.3),
.delta.3.87 (s, 2H, BrCH.sub.2CO), .delta.6.8 (br s, 1H, NH).
Synthesis of meso-tetrakis-2-(N-2-methoxyethylacetamido)pyridyl
porphyrin
[0156] In an oven- and flame-dried flask under argon, were combined
2-PyP (0.015 g, 0.024 mmol) and 2-methoxyethylbromoacetamide (1.0
g, 5.10 mmol) in 2.5 ml anhydrous DMF. The reaction mixture was
heated to 90-100.degree. C. and stirred for 8 h, by which time the
Soret had shifted to 418 nm (H.sub.2O), cooled to room temperature,
and added dropwise to rapidly stirred diethyl ether to precipitate
the porphyrin. The solid was filtered and washed well to yield
meso-tetrakis-2-(N-2-methoxyethylacetamido)pyridyl porphyrin as a
sticky purple solid.
[0157] 1H NMR (300 MHz, CD.sub.3OD): .delta.2.0-3.0 (singlets and
unresolvable protons, 7H, CONHCH.sub.2CH.sub.2OCH.sub.3),
.delta.8.8 (t, 1H, N.sup.+CHCH), .delta.8.9-9.4 (br s, 2H,
pyrrole), .delta.9.1 (t, 1H, N.sup.+CHCHCH), .delta.9.2 (t, 1H,
N.sup.+CCH), .delta.9.56 (q, 1H, N.sup.+CH).
Synthesis of iron(III) chloride
meso-tetrakis-2-(N-2-methoxyethylacetamido)pyridyl porphyrin
[0158] Free base meso-tetrakis-2-(N-2-methoxyethylacetamido)pyridyl
porphyrin was dissolved in deionized water, ferrous ammonium
sulfate hexahydrate was added, and the reaction mixture was
refluxed until the porphyrin Soret shifted to 412 nm and the number
of Q bands had reduced from 4 to 2. The reaction mixture was cooled
to room temperature, and BioRad AG1X8 chloride ion exchange resin
was added and allowed to stir for 2 h. The resin was filtered off,
the filtrate was neutralized, and the solvent was removed by
distillation. The residue was chromatographed on Sephadex LH-20 in
1:1 methanol:water as the eluant. Collection of appropriate
fractions yielded iron(III) chloride
meso-tetrakis-2-(N-2-methoxyethylacetamido)pyridyl porphyrin.
Example 5
Synthesis of Iron(III) chloride
meso-tetrakis-2-(N-(2-methoxyethyl)acetamido)pyridyl porphyrin
Synthesis of 2-bromo-N-(2-methoxyethyl)acetamide
[0159] 2-methoxyethylamine (3.73 g, 0.0496 mol) was dissolved in
dichloromethane (250 ml) and cooled to 0.degree. C. Bromoacetyl
bromide (2.16 ml, 0.0248 mol) was added dropwise, and the reaction
was stirred overnight at room temperature. The reaction mixture was
then washed with water (100 ml) and saturated aqueous sodium
chloride (2.times.100 ml). The organic layer was separated and
dried over anhydrous sodium sulfate, and the solvent was evaporated
under reduced pressure to afford
2-bromo-N-(2-methoxyethyl)acetamide as a white solid in 75%
yield.
[0160] .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.3.4 (s, 3H,
OCH.sub.3), .delta.3.5 (m, 4H, NHCH.sub.2CH.sub.2OCH.sub.3),
.delta.3.9 (s, 2H, BrCH.sub.2), .delta.6.8 (br s, 1H, NH).
[0161] MP (.degree. C.): 33
Synthesis of
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl
porphyrin
[0162] 2-PyP (0.081 g, 1.31.times.10.sup.-4 mol) and
2-bromo-N-(2-methoxyethyl)acetamide (1.0 g, 5.1.times.10.sup.-3
mol) were added to a microwave vial previously purged with Ar
(0.5-2 ml size) and equipped with a stir bar. The vial was sealed
with the provided cap, which was crimped on tightly. The vial was
then heated in an oil bath at 100.degree. C. and stirred for 3 h.
HPLC, monitoring A.sub.418, was used to monitor the progress of the
alkylation of 2-PyP, and to separate the major tetraalkylated
products from one another for identification purposes, as we have
previously described See, Datta, A.; Quintavalla, S. M.; Groves, J.
T., Unusual Alkylation Selectivity in the Synthesis of
Water-soluble 2-pyridyl porphyrins: Kinetic versus Thermodynamic
Control. Journal of Organic Chemistry 2007, 72, (5), 1818-1821.
Isolated tetraalkylated products were identified by .sup.1H NMR.
Once complete, the reaction was cooled to room temperature before
being added dropwise to stirred ether, to precipitate out the
product and remove excess alkylating agent. The resulting
suspension was filtered through a bed of Celite and the porphyrin
was washed through with methanol. The methanol was removed on a
rotary evaporator, and the residue was taken up in H.sub.2O (40 ml)
and washed with dichloromethane (3.times.100 ml). The aqueous layer
was isolated and evaporated under reduced pressure to leave behind
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl porphyrin
as a shiny purple solid in 75% yield.
[0163] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.2.2-2.9
(multiplets and singlets, 28H, NHCH.sub.2CH.sub.2OCH.sub.3),
.delta.5.1-5.6 (doublets and singlets, 8H, N.sup.+CH.sub.2),
.delta.8.77 (m, 4H, N.sup.+CHCH), .delta.8.5-9.4 (br s, 8H,
H.sub.pyrrole), .delta.9.0 (m, 4H, N.sup.+CHCHCH), .delta.9.15 (m,
4H, N.sup.+CCH), .delta.9.55 (m, 4H, N.sup.+CH)
[0164] UV-Vis (H.sub.2O) .lamda. (log .epsilon.): 418 (5.37).
Synthesis of iron(III) chloride
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl
porphyrin
[0165] The iron metallation of
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl porphyrin
was performed according to a literature procedure. Szabo, C.;
Mabley, J. G.; Moeller, S. M.; Shimanovich, R.; Pacher, P.; Virag,
L.; Soriano, F. G.; Van Duzer, J. H.; Williams, W.; Salzman, A. L.;
Groves, J. T., Part I: Pathogenic Role of Peroxynitrite in the
Development of Diabetes and Diabetic Vascular Complications:
Studies with FP15, A Novel Potent Peroxynitrite Decomposition
Catalyst. Molecular Medicine 2002, 8, (10), 571-580. Briefly,
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl porphyrin
(0.065 g, 4.63.times.10.sup.-5 mol) was dissolved in a 0.12 g/ml
aqueous solution of ferrous ammonium sulfate hexahydrate (8 ml) and
raised to reflux in an oil bath. Reaction progress was monitored by
UV-Vis, watching the Soret band broaden and shift from .lamda.=418
nm to .lamda.=412 nm and 2 of the Q bands disappear. The reaction
mixture was cooled, stirred with chloride ion exchange resin (0.4
g) at room temperature for 2 hours, and neutralized with saturated
aqueous sodium bicarbonate. After sitting overnight, the suspension
was filtered through a bed of Celite, and the filtrate was
evaporated down under reduced pressure. The residue was
chromatographed on Sephadex LH-20 in 1:1 methanol:water. The
appropriate fractions were combined and the solvent evaporated
under reduced pressure, to leave iron(III) chloride
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl porphyrin
as a shiny black solid in 89% yield.
[0166] UV-Vis (H.sub.2O) .lamda. (log .epsilon.): 412 (4.80)
Example 6
Preparation of Low-Spin Dicyano Complex for NMR
Characterization
[0167] To a solution of the high-spin chloride complex of iron(III)
chloride meso-tetrakis-2-(N-(2-methoxy)ethyl)pyridyl porphyrin in
D.sub.2O, was added 10 eq of NaCN in D.sub.2O.
[0168] 1H NMR (400 MHz, D.sub.2O): .delta.2.8 (singlets, 12H,
CH.sub.2CH.sub.2OCH3), .delta.3.2-3.6 (m, 8H,
CH.sub.2CH.sub.2OCH.sub.3), .delta.4.4-4.8 (m, 8H,
N.sup.+CH.sub.2), .delta.8.2 (s, 8H, pyrrole), .delta.8.4 (m, 4H,
N.sup.+CHCH), .delta.8.8-9.1 (m, 8H, N.sup.+CHCHCH and N.sup.+CCH),
.delta.9.2 (m, 4H, N.sup.+CH).
Example 7
Evaluation of the Peroxynitrite Decomposition Ability of Iron(III)
Chloride meso-tetrakis-2(N--(N-(2-methoxyethybacetamido)pyridyl
porphyrin
Synthesis of peroxynitrite
[0169] Peroxynitrite was synthesized from hydrogen peroxide and
nitrous acid using an sp250i syringe pump by modification of
published procedures. See, Shimanovich, R.; Groves, J. T.,
Mechanisms of Peroxynitrite Decomposition Catalyzed by FeTMPS, a
Bioactive Sulfonated Iron Porphyrin. Archives of Biochemistry and
Biophysics 2001, 387, (2), 307-317; Saha, A.; Goldstein, S.;
Cabelli, D.; Czapski, G., Determination of optimal conditions for
synthesis of peroxynitrite by mixing acidified hydrogen peroxide
with nitrite. Free Radical Biology & Medicine 1998, 24, (4),
.delta.53-659; and Uppu, R. M.; Squadrito, G. L.; Cueto, R.; Pryor,
W. A., Selecting the most appropriate synthesis of peroxynitrite.
Methods in Enzymology 1996, 269, 285-296; Koppenol, W. H.; Kissner,
R.; Beckman, J. S., Syntheses of peroxynitrite: To go with the flow
or on solid grounds? Nitric Oxide, Part B 1996, 269, 296-302. All
reagents for peroxynitrite synthesis and analysis were degassed
with argon thoroughly before use, and the synthesis was conducted
under an argon atmosphere. Remaining hydrogen peroxide was reduced
to less than 5% (molar ratio) of peroxynitrite with manganese
dioxide (10 mg/ml at 4.degree. C. for 30 min); MnO.sub.2 was
removed through 0.2 .mu.m Supor membrane syringe filter (PALL).
Peroxynitrite concentrations were determined spectrophotometrically
at 302 nm (.epsilon..sub.302=1670 L mol.sup.-1 cm.sup.-1).
Koppenol, W. H.; Kissner, R.; Beckman, J. S., Syntheses of
peroxynitrite: To go with the flow or on solid grounds? Nitric
Oxide, Part B 1996, 269, 296-302. In this manner, the concentration
of peroxynitrite was determined to be 95 mM. The nitrite and
nitrate content in peroxynitrite were estimated by ion
chromatography on a Hamilton PRP X-100 anion-exchange column
(125.times.4 mm), with 2.5% methanol in p-hydroxybenzoic acid (4.0
mM, pH 8.9) as eluent (1 ml/min). Nitrite and nitrate anions were
detected and quantified by measuring the absorbance decrease
(indirect UV detection) at 310 nm. Walker, T. A.; Ho, T. V.;
Akbari, N., The isocratic separation and indirect UV detection of
inorganic anions and mono-carboxylic and di-carboxylic acids on a
low-capacity anion-exchange column. Journal of Liquid
Chromatography 1991, 14, (7), 1351-1366. The concentration of
nitrite was found to be 55 mM, and that of nitrate was 50 mM.
Peroxynitrite was decomposed in 0.14 M HClO.sub.4 prior to HPLC
determination. Kissner, R.; Koppenol, W. H., Product distribution
of peroxynitrite decay as a function of pH, temperature, and
concentration. Journal of the American Chemical Society 2002, 124,
(2), 234-239. Concentrations of hydrogen peroxide in the
peroxynitrite before and after treatment with MnO.sub.2 were
measured by PeroXOquant Quantitative peroxide assay kit (Pierce
Biotechnology), an assay based on the oxidation of Fe.sup.2+ to
Fe.sup.3+ by H.sub.2O.sub.2 under acidic conditions. H.sub.2O.sub.2
measurements were performed after first decomposing peroxynitrite
in phosphate buffer (0.5 M, pH 7.2). The concentration of remaining
H.sub.2O.sub.2 in the peroxynitrite stock after MnO.sub.2 treatment
was 4 mM. Peroxynitrite solutions were prepared by diluting the
stock solution immediately before use with 0.01 M NaOH to achieve
the required concentrations.
Stopped-Flow Spectrophotometric Analysis of Kinetics of
Peroxynitrite Decomposition by Iron(III) chloride
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl
porphyrin
[0170] Iron(III) chloride
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl porphyrin,
the test porphyrin, was reacted with peroxynitrite in a
stopped-flow spectrophotometer in single-mixing experiments using
single-wavelength mode, as we have previously described. Lee, J.;
Hunt, J. A.; Groves, J. T., Mechanisms of Iron Porphyrin Reactions
with Peroxynitrite. J. Am. Chem. Soc. 1998, 120, (30), 7493-7501.
All reactions were carried out in 100 mM phosphate buffer at pH 7.4
and 25.degree. C. by observing changes in the peroxynitrite
absorbance at 302 nm. The concentration of iron(III) chloride
meso-tetrakis-2(N--(N-(2-methoxyethyl)acetamido)pyridyl porphyrin
was varied, and the post-mixing concentration of peroxynitrite was
63 .mu.M.
TABLE-US-00001 [test porphyrin] (.mu.M) t.sub.1/2 (s) 5.15 0.038
6.18 0.024 7.21 0.018 8.24 0.011 9.27 0.0087 10.3 0.0078
TABLE-US-00002 Catalyst k.sub.cat (M.sup.-1 s.sup.-1) Test
porphyrin 1.4 .times. 10.sup.7 FP15.sup.2 7.6 .times. 10.sup.6
Other Embodiments
[0171] It is to be understood that while the invention has been
described in conjunction with the detailed description thereof, the
foregoing description is intended to illustrate and not limit the
scope of the invention, which is defined by the scope of the
appended claims. For example, substituted-pyridyl derivatives,
particularly those including PEG substituents, are particularly
advantageous as peroxynitrite decomposition catalysts. Other
aspects, advantages, and modifications are within the scope of the
following claims.
* * * * *